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     論文内容要旨 
	 医薬品を含む多くの生物活性化合物は光学活性物質であり, その鏡像異性体は異なる生体
内活性を示すことが多いため, 有効な一方の鏡像異性体を高選択的に合成するための不斉合
成反応の開発が重要である. ごく少量の不斉分子によって触媒化される触媒的不斉合成反応
の開発は省エネルギーや環境調和の観点から有機合成化学領域の最も重要な研究課題の一つ
であり, 金属を含有しない有機分子触媒は空気中で安定であり取り扱いやすく安価であると
いう利点なども有するため, 次世代の環境調和型触媒として現在活発に研究開発が行なわれ
ている. 
	 著者は, 新規多点認識型有機分子触媒としてアミノアルコールとスクアラミドが融合した
ハイブリッド型触媒（SFAA 触媒）を設計し, それを, エナンチオ選択的 (1) イサチン類とニ
トロアルケン類との不斉ニトロアルドール反応，(2) 3-ヒドロキシ-2-ピリドン類とマレイミド
類との塩基触媒不斉ディールス・アルダー (DA) 付加環化反応, さらに (3) インダノン類と
1,3-ジカルボニル類とのドミノマイケル付加環化反応にそれぞれ適用し，その有機分子触媒と
しての機能性を検討した.	
(1) SFAA 有機分子触媒 A を合成し, 触媒 A を用いるイサチン類とニトロアルカン類との不
斉ニトロアルドール反応を検討した．その結果, 触媒 A が不斉触媒活性を示し, 本反応によ
って優れた化学収率と良好な光学収率で光学活性オキシインドール誘導体を与えることを見
出した.	 得られるオキシインドール誘導体は，抗癌作用を持つドナキサリジン誘導体などの
有用な合成中間体である． 
(2) SFAA 有機分子触媒 A を用いる 3-ヒドロキシ-2-ピリドン類とマレイミド類との不斉ディ
ールス・アルダー反応を検討した．その結果，触媒 A が不斉触媒活性を示し, 本反応によっ
てほぼ完全な化学収率と優れた光学収率で光学活性イソキヌクリジン誘導体が得られること
を見出した。得られるイソキヌクリジン誘導体は，タミフルなどの抗ウイルス活性化合物の
有用な合成中間体である． 
(3) SFAA 有機分子触媒 A を用いるインダノン類と 1,3-ジカルボニル類との不斉ドミノマイ
ケル付加環化反応を検討した．その結果，触媒 A が不斉触媒活性を示し, 本反応によってほ
ぼ完全な化学収率と優れた光学収率で光学活性スピロ-2-アミノピラン類が得られることを見
出した。得られるスピロ-2-アミノピラン誘導体は，寄生原虫病であるリーシュマニア症に有
効な化合物を合成するための有用な合成中間体である．	
	 本研究において著者は, その分子中に「基質との 3 点の水素結合部位と１点の塩基性部位
を併せ持つ多点認識機能を持つアミノアルコール-スクアラミドハイブリッド型触媒 (SFAA
触媒)」を開発することに成功し, それらが創薬に有効な不斉ニトロアルドール反応，不斉デ
ィールス・アルダー付加環化反応および不斉ドミノマイケル付加環化反応においてそれぞれ
良好な不斉触媒活性を示すことを明らかにした. また，本反応によって得られる化合物は
様々な医薬品をはじめとする生物活性化合物の合成中間体として有用であることから，本研
究の成果は, 新薬創製の合成開発研究に大きく貢献できると期待される. 
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Research summary 
    Many biologically active compounds, including pharmaceuticals, are optically active. Often, only one of 
the enantiomers is required because the enantiomers display different in vivo activities. In pharmaceuticals 
in particular, differences in the absolute configuration can affect not only the pharmacological activity but 
also the toxicity. Catalytic asymmetric synthesis, in which a low amount of a chiral molecular catalyst 
theoretically enables infinite production of an optically active compounds, is among the most important 
current challenges in organic synthetic chemistry; it is also important in terms of energy saving and 
environmental friendliness. Environmental effects now have to be considered in chemical syntheses, and 
environmentally benign organic syntheses have been receiving attention. The chiral catalysts used in 
catalytic asymmetric syntheses can be divided into two categories: organometallic catalysts and metal-free 
chiral organocatalysts. Particularly, organocatalysts are stable in air, easy to handle, and inexpensive, so 
they are being focused on as next-generation, environmentally friendly catalysts.  
    On these backgrounds, author aimed to develop the new hybrid type squaramide fused amino alcohol 
(SFAA) organocatalysts. This SFAA organocatalyst was successfully prepared from commercially available 
amino esters by using simple organic transformations and the catalytic activity were demonstrated in the 
enantioselective (1) nitroaldol, (2) Diels-Alder and (3) domino Michael addition cyclization reactions. 
 
 (1) The enantioselective nitroaldol reaction was established with various isatins and nitromethanes using 
SFAA organocatalysts. This protocol provides chiral 3-substituted 3-hydroxyoxindoles in excellent 
chemical yields and high enantioselectivities. The obtained 3-substituted 3-hydroxyoxindoles are important 
synthetic precursors for many biological active and natural compounds such as donaxaridine (anti-cancer 
drug). 
(2) The enantioselective Diels-Alder reaction was established with 3-hydroxy-2-pyridones and maleimides 
using SFAA organocatalysts. This protocol provides the chiral 4-hydroxyisoquinnuclidines in both excellent 
chemical yields and enantioselectivities. The obtained chiral 4-hydroxyisoquinnuclidines are synthetic 
intermediates for many biological active compounds such as oseltamivir phosphate (anti-influenza drug). 
(3) The enantioselective domino Michael addition cyclization reaction was established with 3-dicyano-2-
indanones and 1,3-cyclic carbonyl compounds using SFAA organocatalysts. This protocol provides the 
chiral spiro-conjugated 2-aminopyrans in both excellent chemical yields and enantioselectivities. The 
obtained chiral spiro-conjugated 2-aminopyrans are significant synthetic intermediates for many biological 
compounds such as 2-amino-tetrahydrochromene (anti-leishmaniasis). 
     
    In this study, author revealed that the new explored new hybrid type squaramide fused amino alcohol 
(SFAA) organocatalyst having both three hydro-bonding sites and a basic site in the compound with a 
substrate shows satisfactory catalytic activity in the enantioselective (1) nitroaldol, (2) Diels-Alder and (3) 
domino Michael addition cyclization reactions. It is expected that this result might be able to greatly 
contribute the development of new drug and its related compounds.  
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1.1 Introduction 
 The enantioselective organocatalysis is most important and well-explored area in synthetic 
organic chemistry for synthesizing biological active chiral molecules. Because of its does not 
involve any toxic metals or costly enzyme catalysts to carry out the stereoselective organic 
reactions. From the last few years, organocatalysis leading explored into one of the most 
breathtaking and precipitously emerging area in synthetic organic chemistry.1,2 The 
enantioselective synthesis provides a practical and cost-effective synthesis of chiral molecules, but 
designing of simple and efficient synthetic strategies are interesting and often more challenging.  
 
 Author PhD objectives were to design and develop the new hybrid type squaramide fused 
amino alcohol (SFAA) organocatalysts for asymmetric reactions. The new hybrid type SFAA 
oragnocatalysts were developed and used in this thesis mainly concentrated on four sections (i) 
The development new hybrid type squaramide fused amino alcohol organocatalysts, (ii) Nitro-
aldol (Henry), (iii) Diels-Alder and (iv) Domino Michael addition cyclization reactions. The brief 
discovery and applications of these enantioselective reactions are discussed in the following 
sections.  
 
1.2 Catalysis 
 The catalysis mainly classified in to three major parts, such as metal, enzyme and 
organocatalysis. Currently, enantioselective organocatalysis is known as an independent synthetic 
research area among enantioselective metallic catalysis and enzymatic catalysis for the synthesis 
of optically active compounds. Among the metal and enzyme catalysis, the organocatalysis gains 
its own importance’s due to non-toxic, availability and easy to synthesis. They are mostly stable 
under aerobic conditions, and the organocatalytic reactions do not require very dry conditions to 
carry out the reactions.3  
 
 
 
 
 
 
 
 3 
1.3 Chirality  
 According to Mislow,4 for chiral molecule the definitions is defined as follows "A molecule 
may be chiral if it is non-identical to its mirror images" if it not obeys the above said definition 
such compounds are known be achiral, the chirality concept can be also explained by following 
way, our right and left hands are mirror images of each other, but cannot be superimposed on each 
other when palms are fronting to the same direction. The below depicted generic chiral amino acid 
is able to exist as mirror images of each other. (Figure 1).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Two enantiomers of a generic amino acids 
 
1.4 Asymmetric synthesis and its importance 
 Asymmetric synthesis as defined by Morrison and Mosher,5 is a chemical reaction in which 
an achiral unit in a group of molecules is converted into a chiral unit, in such course of reaction 
unequal amounts of stereoisomers are produced. For example, the (R)-thalidomide shows the 
activity towards for morning sickness, while the (S)-thalidomide causes the embryo growth 
restriction or death of embryo (Figure 2).  
 4 
 
 
 
 
 
 
Figure 2. Biological role of thalidomide isomer 
 Ibuprofen is a nonsteroidal anti-inflammatory drug, in human body its functions as an 
antipyretic and analgesic agent. Ibuprofen is commonly used for treatment of acute and chronic 
pain, osteoarthritis, rheumatoid arthritis diseases. The pharmacokinetics of ibuprofen differs as the 
in form of R-(-)-ibuprofen and S-(+)-ibuprofen (Figure 3), in which the (S)-ibuprofen shows anti-
inflammatory activity while (R)-ibuprofen is found to be non-active.6  
 
 
 
 
 
 
Figure 3. The biological role of ibuprofen isomers 
 
1.5 Advantages of organocatalysis 
 The advantages of organocatalysis gains its own consideration when compared to metal 
and enzyme catalysis, because the catalysts are usually inexpensive and easy to synthesis and 
widely available in a large number, suitable for small-scale to gram-scale reactions, additionally 
catalysts are non-toxic and eco-friendly. By these own advantages of organocatalysts many 
researchers are focused in development new class of catalysts for enantioselective reactions. For 
example, the following organocatalysts are widely and well-studied in the field of synthetic 
organic chemistry. (Figure 4).7 
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Figure 4. Widely used organocatalysts in asymmetric synthesis 
 
1.6 Covalent modes of activation 
 In covalent modes of activation iminium and enamine catalysis are well studied in 
enantioselective synthesis. The iminium catalysis involves the condensation of a secondary amine 
with an electrophilic carbonyl containing as substructure, which generates the electrophilic 
iminium cation species which are attacked by appropriate nucleophiles to form a chiral product 
(Scheme 1).8 Regarding to enamine catalysis is one of the very examined exploration study in the 
area of enantioselective catalysis. Enamine activation perception is as follows the reversible 
condensation of an amine catalyst of electron deficient carbonyl compounds to form an iminium 
intermediate that, upon tautomerization to generate the enamine reactive species which is reacts 
with an available electrophile. 
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Scheme 1. Covalent modes of activation 
 
As an example of covalent modes of activation (S)-proline, b-amino alcohols and imidazolidinone 
catalysts (Figure 5) are well explored in enantioselective synthesis.9 
  
 
 
 
 
Figure 5. Covalent type organocatalysts  
 
1.7 Non-covalent modes of activation 
 In non-covalent modes of activation usually hydrogen bond-donor catalysis plays a 
primitive role for activation of substrates, which is a well explored research area in enantioselective 
catalysis. Among them, non-covalent modes of activation squaramide and thiourea based 
organocatalysts are well studied.10 The squaramide catalyst usually forms a multiple hydrogen 
bonding’s mode with the substrates (mainly electron deficient conjugated ketones) which allows 
an electrophilic site to attack an appropriate nucleophile on it to which subsequently affords the 
chiral products (Scheme 2). 
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Scheme 2. Non-covalent modes of activation 
 
The chiral phosphoric acids, phase transfer catalyst and cinchona based squaramide catalysts are 
well explored in field of non-covalent organocatalysts (Figure 6). 
 
 
 
 
 
 
 
Figure 6. Non-covalent type organocatalysts 
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1.8 b-Amino alcohol organocatalysis in asymmetric synthesis 
  The simple b-amino alcohols and their derivatives can be easily prepared in a single-step 
from their related compounds such as accessible amino acids. These chiral precursors could be 
serves as an independent chiral catalyst in enantioselective organocatalysis.11 There are many 
benefits of using simple primary b-amino alcohols as new class of organocatalysts, such as easy 
to prepare, stability on air/water, and which can be used as both covalent (iminium) and non-
covalent (hydrogen bonding donor) interactions. 
 
 
 
Scheme 3. Preparation method for b-amino alcohols 
 
The b-amino alcohols can be easily prepared from corresponding amino acids ester salts using 
simple organic transformation (Scheme 3). The simple primary b-amino alcohols can be easily 
derived in to a di amino alcohol, aza-norbornane type amino alcohol and silyl protected amino 
alcohol as organocatalysts. By introducing new functional groups on amino alcohol catalyst, there 
might be possibility in increasing the enantiomeric phase of catalysts. The primary b-amino 
alcohols and their derivatives successfully showed the catalytic activity in important asymmetric 
reaction such as Diels-Alder and 1,3-dipolar cycloadditions, Aldol and cross-aldol reactions to 
afford the valuable chiral biological synthetic intermediates in satisfactory chemical yields and 
enantioselectively (Scheme 4).12 
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Scheme 4. The b-amino alcohol organocatalysts for enantioselective reactions 
 
1.9 Recent progress in squaramide organocatalysis 
 The first example bearing squaramide unit in enantioselective synthesis was described by13 
W. Xie and his research is for the enantioselective reduction of pro-chiral ketones which stood by 
with borane dimethyl sulfide in the presence of chiral squaramide amino alcohols catalyst (Scheme 
5), to afforded chiral secondary alcohols in excellent enantioselectivities (99 % ee). 
 
 
 
Scheme 5. Bicyclic amino alcohol squaramide organocatalysts for reduction of prochiral ketones  
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 V. H. Rawal and his research group demonstrated cinchona based squaramide catalyst in 
enantioselective Michael reaction with active C-H functions of nitroalkenes, which afforded 
anticipated Michael products in both satisfactory chemical yields and enantiomeric excess 
(Scheme 6).14 
 
 
Scheme 6. Cinchona based squaramide organocatalysts for Michael addition reaction 
 
 Furthermore, V. H. Rawal and his research group15 has also reported the enantioselective 
Friedel-Craft reaction of indoles with arylsulfonylimines using with cyclohexyl amine derived 
squaramide organocatalyst (Scheme 7). The organocatalysts was afforded the indolyl-
sulfonamides, in good excellent chemical yield (up to 96%) and in excellent enantioselectivities 
(up to 96% ee). 
 
 
Scheme 7. Cyclohexyl amine based squaramide catalysts for Friedel-Craft reaction 
 
 C. Tang and his research group16 reported the tandem Michael addition and intramolecular 
cyclization concept with Michael donors and ortho-hydroxynitroolefines to afford the chiral 2-
aminopyrans using cyclohexyl diphenyldethyleneamine derived squaramide oragnocatalyst. The 
catalyst was found to be good H-bonding catalyst for affording the chiral 2-aminopyrans in good 
to excellent enantioselctivities (41-95%), using with 10 mol % of oragnocatalyst (Scheme 8). 
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Scheme 8. Cyclohexyl diphenyl diethylamine derived squaramide catalyst for Michael addition 
 
1.10 Structural judgement of thioureas between squaramides 
The squaramide have the its own structural arrangements and works very effectively when 
compared to thiourea and guanidine type of catalysts. The following figure represents the bond 
distances and resonance on thioureas and squaramido units (I-IV).17 The two -NH functions bond 
forming distance is measured practically as 2.13 Å of thiourea (I), the thiourea units exhibits the 
resonance effect from sulphur atom to -NH functions (II-III). In the case of squaramido unit the 
two -NH functions bond forming distances is 2.71Å (IV), the resonance effect is allowing from 
oxygen atoms of cyclobutanedione ring towards -NH functions of squaramido unit (V-VI). 
 
  
 
 
 
 
 
Figure 7. Structural comparisons between thiourea and squaramide unit 
 
1.11 General preparation method for squaramide organocatalysts 
 The squarate esters was easily prepared from squaric acid, which is also called as quadratic 
acid because of its four carbon atoms approximating to from a square, is an organic compound 
with chemical formula C4H2O4. Squaric acid is also used as reagent for chemical synthesis, used 
for instance to make photosensitive squaric dyes and inhibitors of protein tyrosine phosphatases. 
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Recently the squarate esters were gained importance in field of organocatalysts, and its widely 
explored as starting materials for synthesizing many squaramide bifunctional organocatalysts. In 
addition, the synthesis involves a condensation reaction with dimethyl squarate of amine a, again 
respected by a parallel substitution reaction using with a chiral primary amine c affording the 
bifunctional squaramide units d (Scheme 9).18 
 
 
 
 
 
Scheme 9. Common synthesis method for the squaramide organocatalysts 
 
1.12 Binding modes of squaramide motif with different substrates 
 The squaramide motif is serves as an effective activation function for hydrogen bonding’s 
with variety of substrates such as nitro-olefins (VII), conjugated ketones (VIII), pyruvate ketones 
(IX), oxazolidinone ketones (X) and imino-ester (XI) (Figure 8).19  
  
 
Figure 8. Possible bindings modes of squaramides unit to various hydrogen bonds acceptors 
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1.13 Author strategy 
Author aimed to develop new hybrid type squaramide fused amino alochol organocatalysts 
by using simple primary b-amino alcohol as chiral precursors, the squaramide organocatalysts are 
remarkable four membered ring systems derived from squaric acid. The squaramide unit of the 
catalyst part can contribute two proximate and polarized -NH fragments (Figure 9). The 
squaramide catalysts function as an effective activation unit for hydrogen-bond donor catalysis 
when compared with urea/thiourea and guanidine type catalysts. By these advantages of 
squaramide catalysts author concentrated to the synthesis of usual and new hybrid type squaramide 
fused amino alcohol organocatalysts by using amino alcohols. 
 
 
 
 
 
 
Figure 9. General structure of squaramide organocatalysts 
 
However, recently the usual type squaramide fused amino alcohols are reported in the literature 
by Hari C. Bajaj20 and his research group described the synthesis of usual type squaramide fused 
amino alcohol organocatalysts using with b-amino alcohol as chiral precursors having isopropyl 
and phenyl groups at side chain of the catalyst (Scheme 10). And demonstrated their catalytic 
activity in enantioselective allylation reaction of isatins with allyl tributyltin to afford the 
corresponding chiral 3-allyl-3-hydroxyindoles in high and enantioselectivities. Moreover, the 
usual type squaramide fused amino alcohol organocatalysts contains only hydrogen bonding and 
steric influences on the molecule. 
Scheme 10. Enantioselective allylation of isatins 
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And its didn’t have any basic site to abstract the proton from pro-nucleophiles to affords high 
enantioslectivities, additionally, the usual type squaramide fused amino alcohol organocatalysts 
are not well studied in the field of enantioselective synthesis. By these drawbacks of usual type 
squaramide fused amino alcohol organocatalysts, author aimed to synthesis new hybrid type 
squaramide fused amino alcohol organocatalysts by introducing Brønsted basic site on the 
molecule. After several attempts, author successfully developed the new hybrid type squaramide 
fused amino alcohol (SFAA) having multiple activation sites such as two amino and one hydroxy 
group as the hydrogen-bonding sites, three steric influences from phenyl groups and side chain of 
the SFAA catalysts contains cyclic tertiary amino group that can act as a Brønsted base. And two 
amino and one hydroxy group that can form hydrogen bonds with both substrates. By owing these 
properties of SFAA catalysts might be act as trifunctional organocatalysts (Scheme 11).  
 
 
 
 
 
 
 
 
 
 
Scheme 11. Concept of SFAA catalyst design 
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The newly developed hybrid type SFAA organocatalysts having hydrogen bonding, steric 
influences and Brønsted basic sites demonstrated its catalytic activity for enantioselective reactions 
such as nitro-aldol reaction, Diels-Alder reaction and domino Michael addition cyclization 
reaction to afford the corresponding biologically active synthetic intermediates in high 
enatioselectivities.  
i) Enantioselective nitro-aldol reaction 
 Author initially tried and explored the catalytic activity of SFAA organocatalysts for 
enantioselective nitro-aldol reaction of isatins with nitromethane to affords the chiral 3-alkyl-3-
hydroxyoxindoles in excellent chemical yields (up to 99% yield) and enantioselectivies (up to 95% 
ee). The chiral 3-alkyl-3-hydroxyoxindoles are the prominent synthetic intermediates for many 
biologically active compounds. Such as the donaxaridine (anticancer), spirobrasinin (antifungal), 
maremycin B (cytotoxicity), CPC-1 (antibacterial agent) and dioxibrasinin (natural product) 
(Scheme 12).21 
 
Scheme 12. SFAA organocatalyst for enantioselective nitro-aldol reaction 
ii) Enantioselective Diels-Alder reaction 
 Furthermore, the author has applied the newly prepared SFAA organocatalysts for 
enantioselective Diels-Alder reaction of 3-hydroxy-2-pyridones with dienophiles to accesses the 
chiral 4-hydroxyisoquinuclidines in both excellent chemical yield (up to 98%) and 
enantioselectivities (up to 98%) (Scheme 13).22 The chiral 4-hydroxyisoquinnuclidines are key 
synthetic intermediates for bicyclic complex structures and many biological active compounds 
such as oseltamivir (antiinfluenza drug), ibogaine (psychoactive drug) and vinblastine and 
vincristine (anticancer drugs). 
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Scheme 13. SFAA organocatalysts for enantioselective Diels-Alder reaction 
 
iii) Enantioselective domino Michael addition cyclization reaction   
 Moreover, author also successfully applied the SFAA organocatalysts for enantioselective 
domino Michael addition cyclization reaction of 3-dicyano-2-indanones with cyclic 1,3-dicarbonyl 
compounds for affording the chiral spiro-conjugated 2-aminopyrans in both excellent chemical 
yield (up to 97% yield) and enantioselectivities (up to 95% ee). The domino Michael addition 
cyclization reaction of electron withdrawing indanones with active methylene’s accesses the chiral 
quaternary streogenic 2-aminopyrans. The chiral spiro-conjugated 2-aminopyrans are the vital 
synthetic intermediates for many biologically active derivatives, such as tacrine derived 2-
aminopyrans (antialzheimers), spiro-pyranopyrazoles (antioxidants), pyranopyranones 
(anticoagulant) and 2-aminotetrahydrocromenes (antileishmaniasis) (Scheme 14). The detailed 
discovery of SFAA organocatalysts preparations and its application for enantioselective reactions 
will be discussed in following sections. 
 
 
 
Scheme 14. SFAA organocatalysts for enantioselective domino Michael addition cyclization 
reaction 
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Chapter 2 
The New Hybrid Type Squaramide Fused Amino Alcohol 
Organocatalysts For Enantioselective Nitro-Aldol Reaction of 
Nitromethane with Isatins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
2.1 Introduction 
 The nitro-aldol reaction is also referred as (Henry reaction) which is a well-studied reaction 
in synthetic organic chemistry. The nitro-aldol reaction was discovered by Belgian chemist Louis 
Henry during the year of 1895. The nitro-aldol reaction is the usually takes place between 
nitroalkane and an electron deficient (ketone/aldehyde) in the presence of catalytic amount of basic 
additives to afford the b-nitro alcohol. The obtained b-nitroalcohols can be easily converted into 
other functional derivatives such as, nitroalkenes, a-nitro ketones and b-amino alcohols (Scheme 
15).23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 15. General representation of nitro-aldol reaction 
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2.2 Mechanism 
 The nitro-aldol reaction mechanism leads with deprotonation of nitro-alkane in the 
presence of base which forms carbanion at a-position. The active species of carbanion reacts with 
electron deficient (ketone/aldehyde) to form the diastereomeric b-nitro alkoxide. The protonation 
of the alkoxide from the reaction medium forms the b-nitro alcohol as desired product. In nitro-
aldol course of reaction all the steps are reversible (Scheme 16).24  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 16. Mechanism of nitro-aldol reaction 
 
2.3 Stereochemical course of the nitro-aldol reaction 
 In a stereochemical course of the nitro-aldol reaction usually produces the unequal amount 
of the isomers. In many enantioselective nitro-aldol reactions syn or anti-isomer can be observed 
in the course of the reaction. The steric influences of the substrates usually determine the 
stereochemical outcome of the products in nitro-aldol reaction (Scheme 17).25 
 
 
 
 
  
   
 
Scheme 17. The anti/syn stereochemical approach of nitro-aldol reaction  
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When it’s come to the one chiral center bearing of nitro-aldol products the stereochemistry 
assigned as (R) or (S) its depends on the R groups on the substrates of ketone/aldehyde and 
nitroalkane. The stereochemistry of resultant nitro-aldol products also obeys the enantiomeric face 
approach of the corresponding nitromethane to electrophilic ketones (Scheme 18). 
 
 
 
 
 
 
Scheme 18. (S) or (R) enantiomers of the nitro-aldol reaction 
 
2.4 Limitations of the nitro-aldol reaction 
 The main drawback of the nitro-aldol reaction is producing the potential side products in 
the course of the reaction. In the following reaction the nitromethane reacts with ketone in the 
presence of basic medium to form the nitro-aldol adduct. The nitro-aldol adduct has the tendency 
to undergo retro nitro-aldol reaction to afford retro nitro-aldol product (nitro-alkene) in the 
presence of protic solvent medium. (Scheme 19). 
 
 
 
 
 
 
Scheme 19. General representation of the retro nitro-aldol reaction 
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2.5 The enantioselective nitro-aldol reaction of isatins with nitroalkanes 
 The enantioselective nitro-aldol reaction of isatins with nitroalkanes affords synthetically 
valuable chiral 3-alkyl-3-hydroxyoxindoles.26 The 3-substituted 3-hydroxyoxindoles are the core 
structural unit in a large array of fascinating natural products with broad spectrum of intriguing 
biological activities (Scheme 20). The resulting heterocycles are important synthetic precursors 
for many biologically active natural products such as CPC-1 (antibacterial activity), maremycin B 
(cytotoxicity against K562 human leukemia cell lines), spirobrassinin (anti- fungal, antitumor, and 
oviposition stimulation activity), 	 donaxaridine (anticancer activity), and dioxibrassinin 
(important natural product).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20. General representation of the nitro-aldol reaction of isatins with nitroalkanes using 
organocatalyst 
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 W. Wang and his research group27 reported enantioselective nitro-aldol reaction of isatins 
1 with nitroalkanes 2 using cupreine 3 as organocatalyst to afford the nitro-aldol adducts in 
excellent yields (up to 98%) and with good to excellent enantioselectivities (up to 99%) under the 
mild reaction conditions (Scheme 21). And this strategy relying on non-covalent bond-mediated 
catalysis which is a different approach from other organocatalytic of nitro-aldol reaction. In this 
methodology, they also demonstrated the synthetic utility of 3-susbstituted 3-hydroxyoxindoles 4 
to afford (S)-(-)-spirobrassinin 5. The (S)-(-)-spirobrassinin is a natural product isolated from 
Pseudomonas cichorii (Japanese radishes) in 1987. The compound displays various biological 
properties including plant defense, antifungal and antitumor activities. 
 
 
 
  
 
 
 
 
 
 
Scheme 21. The enantioselective nitro-aldol reaction using cupreine alkaloid 
 
 X. -W. Wang and his research group28 reported the enantioselective nitro-aldol reaction of 
isatins with nitroalkanes using with bifunctional cinchona alkaloid derivatives as organocatalysts. 
In the course of enantioselective nitro-aldol reaction they prepared a series of cinchona alkaloid 
derivatives 8a-f, among them 8f has showed the excellent catalytic activity in enantioselective 
nitro-aldol reaction of isatins 6 with nitromethane 7 to afford 3-hydroxy-3-(nitromethyl)indolin-2-
ones 9 in both excellent yields (up to 98%) and enantioselectivities (up to 95%) (Scheme 22).  
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Scheme 22. The enantioselective nitro-aldol reaction of isatins with nitromethane using cinchona 
alkaloids 
 
 Pravin R. Likhar and his research group29 reported the enantioselective nitro-aldol reaction 
of isatins 10 with nitromethane 7 in the presence of bis-cinchona based (DHQD)2PHAL 11 
alkaloid as organocatalyst. They prepared a series of bifunctional cinchona alkaloid catalysts 
possessing pthalazine as a cross linker in between two cinchona alkaloids. They successfully 
demonstrated the prepared catalysts catalytic activity in enantioselective nitro-aldol reaction to 
afford the 3-hydroxyoxindoles 12 in both good to excellent chemical yields (up to 98%) and 
enantioselectivities (up to 97%) (Scheme 23). 
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Scheme 23. The enantioselective nitro-aldol reaction using cinchona based (DHQD)2PHAL  
 
 Wang and his research group30 has reported the organocatalytic enantioselective nitro-aldol 
reaction of isatins 13 with nitromethane 7 using cinchona alkaloid catalysts 14a-d, among them 
catalyst 14d have showed the excellent catalytic activity for affording the 3-hydroxyoxindoles 15 
in excellent yield (up to 96%) and high enantioselectivites (up to 92%). And this method 
effectively useful for the synthesis of (R)-(+)-dioxibrasinin 16, the dioxibrasinin belongs to 
phytoalexins class, with possessing potent antimicrobial activity (Scheme 24).  
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Scheme 24. The enantioselective nitro-aldol reaction using cinchona alkaloids 
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2.6 Author strategy  
 As part of author research work aim to develop the simple primary b-amino alcohols as a 
new class of organocatalysts in enantioselective synthesis. Author successfully prepared the new 
hybrid type squaramide fused amino alcohol (SFAA) organocatalysts using with simple primary 
b-amino alcohol as chiral precursors. The SFAA catalysts posses with distinctive properties such 
as ease to synthesis, stability upon exposure to air, potential towards steric site modifications, and 
capability act as trifunctional (enamine activation, non-covalent activation and basic site) catalyst. 
The SFAA catalysts can be a more hydrogen bonding possibilities compared to those with 
urea/thiourea and guanidine catalyst providing more superior rate of enhancements and 
stereoselective controls in enantioselective reactions. An advantage of chiral SFAA as 
organocatalysts is the simple and modular preparation, which offers a facile route to a wide range 
of trifunctional organocatalysts. By this point of view, author synthesized the new hybrid type 
SFAA organocatalysts which contains a cyclic tertiary amino group that can act as a Brønsted 
base, sterically bulky groups, and two amino and one hydroxy group that can form hydrogen bonds 
with both substrates (Scheme 25). The SFAA catalysts X and Y can be easily prepared by the 
condensation reaction of a squaramide and the corresponding amino alcohol.  
 
 
 
 
 
 
 
 
 
Scheme 25. Properties of squaramide fused amino alcohol organocatalysts X and Y 
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2.7 Results and discussions 
 The newly developed SFAA organocatalysts posses with multiple hydrogen bonding sites 
and steric influence sites within one molecule, it might have shown strong stereochemical 
influence in the enantioselective nitro-aldol reaction of isatins with nitromethane. As shown in the 
plausible transition state Z, where isatin and nitromethane can be conformationally fixed by four 
hydrogen-bonding interaction, that is between the two amino groups of the squaramide and the 
two carbonyl groups of the isatins. Between the cyclic ammonium site of squaramide and oxygen 
atom of the nitro enolate moiety, and between the cyclic ammonium site and the hydrogen atom 
of the hydroxy group in the ammonium alcohol intermediate (Scheme 26). Then, the reaction may 
proceed stereoselectively to afford the nitro-aldol product with high enantioselectivity.  
 
 
 
 
 
 
 
 
 
 
Scheme 26. Conceptualization of enantioselective nitro-aldol reaction using SFAA 
oraganocatalysts 
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2.7.1 Synthesis of usual type squaramide fused amino alcohol organocatalysts 
 Initially, according previous literature procedures,20 author prepared usual type of 
squarmide fused amino alcohol organocatalysts by employing coupling reaction of squarate 
monoester amide with corresponding b-amino alcohol which were easily prepared from Grignard 
reaction of commercially available amino esters salts.  First, author synthesized a series of amino 
acids ester salts 18 from corresponding amino acids 17 by reaction with thionyl chloride at 0 °C - 
rt conditions, the amino acids salts were obtained with excellent yields up to 99% (Scheme 27). 
 
 
  
Scheme 27. Synthesis of amino acid salts from amino acids 
 
The obtained amino acids salts were reacted with PhMgBr in argon atmosphere to using dry ether 
at 0 °C temperature to afford the b-amino alcohols organocatalysts 19a-d in moderate yields up to 
48-59% (Scheme 28). Furthermore, the obtained b-amino alcohol organocatalysts 19a-d were 
fused with squaramide mono ester amide 20 in dry MeOH solvent at room temperature to furnish 
the usual type squaramide fused amino alcohol organocatalyst 21a-d in moderate to good yields 
59-70% (Scheme 29) 
  
 
 
 
Scheme 28. Synthesis of b-amino alcohol organocatalysts from amino acid salts 
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Scheme 29. Synthesis of usual type squaramide fused amino alcohol organocatalysts 
 
2.7.2 Synthesis of new hybrid type squaramide fused amino alcohol organocatalysts  
 Furthermore, by employing previous literature procedures11 author prepared new type 
hybrid squaramide fused amino alcohol organocatalysts from using L-Serine amino acid 22 as 
starting material. The serine was reacted with thionyl chloride in MeOH at 0 °C to afford the serine 
methyl ester hydrochloride salt 23 with 99% yield. The obtained salt 23 were reacted with PhMgBr 
to afford the serine b-amino alcohol 24 with 54% yield (Scheme 30). Moreover, the amino group 
of obtained serine amino alcohol 24 was protected with (Boc)2O to afford compound 25 with 91% 
yield. 
 
 
 
 
 
Scheme 30. Synthesis of serine b-amino alcohol 
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Next, the primary hydroxy group of compound 25 protected with MsCl in the presence of Et3N to 
afford 26 with 81% yield. Furthermore, the compound 26 reacted with cyclic amines (pyrrolidine, 
piperdine, azapane, morpholine and thiomorpholine) in neat reaction conditions to afford the 
compounds 27a-e in 55-65% chemical yields respectively. The Boc group on nitrogen function of 
compounds 27a-e was de-protected using with excess amount of TFA in dichloromethane as 
solvent at 0 °C to afford the desired amino alcohols 28a-e with 85-95% yields. The obtained 
diamine alcohol 28a-e were fused with squramide mono ester amide 20 using MeOH in sealed 
tube at 120 °C for 12h to afford the targeted new hybrid type squaramide fused amino alcohol 
organocatalysts 29a-e in moderate to good yields (up to 81%) (Scheme 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 31. Synthesis of new hybrid type squaramide fused amino alcohol organocatalysts 
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The newly synthesized hybride type squaramide fused amino alcohol organocatalysts were 
characterized with 1H-NMR, 13C-NMR, HRMS, and IR spectroscopy. Next, author examined the 
catalytic activity of prepared catalysts 29a-e for enantioselective nitro-aldol reaction of isatins 30a-
c with nitromethane 7. 
 
2.7.3 The nitro-aldol reaction of isatin with nitromethane using catalysts 21a-d 
 Author desire to examine the catalytic activity of catalysts 21a-d for enantioselective nitro-
aldol reaction (Table 1), initially, author carried out the reaction of simple isatin 30a with 
nitromethane 7 using catalyst 21a in THF at 0 °C without using of any basic additives. However, 
the expected aldol product 31a was not observed even after 48h and the starting compound 30 
recovered completely (entry 1). Then author hypothesized that addition of a basic additive might 
initiate the reaction. To implement this hypothesis, the basic additives such as TEA, DIPEA and 
DMAP were used in the course of reaction to abstract the proton from nitromethane (entries 2-4). 
 
Table 1.  Enantioselective nitro-aldol reaction using catalysts 21a-d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
O
O
N
O
HO NO2
CH3NO2
R R
DMAP, solvent
0 oC, 48 h
21a-d (10 mol %)
30a-c 7 31a-c
catalysts
entrya catalysts 
21a-d R base solvent yield [%]
b ee [%]c
1d
2
3
4
5
6
7
8
9
10
11
a
a
a
a
b
c
d
a
a
a
a
H
H
H
H
H
H
H
Me
Bn
H
H
---
TEA
DIPEA
DMAP
DMAP
DMAP
DMAP
DMAP
DMAP
DMAP
DMAP
THF
THF
THF
THF
THF
THF
THF
THF
THF
DCM
CHCl3
31a-c
--- --- ---
a
a
a
a
a
a
b
c
a
a
12 8
25 11
83 38
82 32
83 31
82 32
62 23
75 11
92 rac
85 rac
aThe reaction were carried out with 30a-c (0.13 mmol), 7 (0.67 mmol) in above 
mentioned solvents (2.0 mL).  bIsolated yields. cEnantiomeric excess was 
determined on chiral HPLC using Chiralpak AD-H column. dWithout using any base
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By using these basic additives, the reaction was proceeded smoothly and afforded aldol product 
31a, but the better results was observed by using DMAP as additive (entry 4, 83%, 38% ee). Then, 
different SFAA catalysts 21b-d were tested and each catalyst showed considerable catalytic 
activity and furnished the product 31a in good yields (up to 83%), although the enantioselectivities 
was not satisfactory obtained (entries 5-7, up to 32% ee). Among the examined catalysts, 21a was 
found to be the best one to afford aldol product 31a in good chemical yield, although the 
satisfactory enantioselectivity was not afforded. Furthermore, different substituted isatins were 
examined using catalyst 21a under the same reaction conditions. The reactions of N-methylated 
isatin 30b and N-benzylated isatin 30c respectively, afforded the corresponding aldol products 31b 
and 31c in moderate chemical yields with poor enantioselectivities (entries 8, 9). The nitro-aldol 
reaction was performed in different polar and non-polar solvents. The reaction proceeded 
efficiently in DCM and CHCl3 respectively, the aldol product 31a were obtained in good chemical 
yield, although in racemic (entries 10, 11). These results shown that catalysts 21a-d were 
inefficient to afford the aldol products with satisfactory enantioselectivities and it revealed that a 
basic additive is necessary to proceed the reaction. By observed results in (Table 1) author assumed 
that the introduction of basic site into the core structure of SFAA catalyst could improve the 
enantioselectivity of the nitro-aldol reaction. 
 
2.7.4 Nitro-aldol reaction using catalysts 29a-e 
 Next, author examined the catalytic activity of catalysts 29a-e using the best solvent i.e. 
THF (Table 2). As the first attempt, catalyst 29a bearing pyrrolidine ring system as a basic site 
was tested in the nitro-aldol reaction of simple isatin 30a with nitromethane 7 at 0 °C. As expected, 
aldol product 31a was obtained in excellent chemical yield (99%) with moderate enantioselectivity 
(64% ee) (entry 1). Furthermore, author examined the catalytic activity of other SFAA catalysts 
29b-e for this reaction. Catalyst 29b bearing piperidine ring system afforded 31a with excellent 
chemical yield (92%) but with low enantioselectivity (39%) (entry 2). The best enantioselectivity 
(81% ee) with good chemical yield (92%) was obtained by using catalyst 29c bearing azepane ring 
system (entry 3). On the other hand, other two catalysts bearing morpholine and thiomorpholine 
ring systems 29d-e, afforded the nitro-aldol product 31a in only trace amounts (entries 4, 5). 
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Table 2. The enantioselective nitro-aldol reaction using catalysts 29a-e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fortunately, performing these reactions at room temperature successfully afforded the desired 
aldol product 31a in good chemical yields with moderate enantioselectivities (29d: 85%, 61% ee; 
29e: 98%, 59% ee) (entries 6, 7), but these results were not better than those obtained with catalyst 
29c. From these observed results, the catalyst 29a is superior in the nitro-aldol reaction of isatin 
30a with nitromethane 7. Furthermore, author investigated optimization reaction condition for 
enantioselective nitro-aldol reaction using catalyst 29c with isatin 30a and nitromethane 7. 
 
2.7.5 Optimization of nitro-aldol reaction conditions using catalyst 29c 
 Author next inspected the effect of solvent, molar ratio of catalyst, and reaction temperature 
(entries 1-20, Table 3). Changing the molar ratio of catalyst 29c to 5 mol% and 20 mol% also 
provided the aldol product 31a in good chemical yields and enantioselectivity (5 mol%: 82%, 74 
% ee, 20 mol%: 93%, 64% ee), respectively (entries 1, 2). Author also optimized the nitro-aldol 
reaction at lower temperature (-20 oC), in these reaction condition author observed decreases in 
both the chemical yield (70%) and enantiomeric excess (78%) (entry 3).  
N
H
O
O
N
H
O
HO NO2
CH3NO2
THF, 60 h
30a 7 31a
entrya catalysts 29a-e temp. (°C) ee [%]c
1
2
3
4
5
6
7
a
b
c
d
e
d
e
0
0
0
0
0
RT
RT
yield [%]b
99 64
92 39
92 81
trace ---
trace ---
85
98
61
59
catalysts 29a-e
(10 mol %)
aThe reaction were carried out with 30a (0.13 mmol), 
7 (0.67 mmol) in dry THF (2.0 mL). bIsolated yields. 
cEnantiomeric excess was determined by chiral
 HPLC on chiralpak AD-H column
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Table 3. Optimization of reaction conditions using catalyst 29c 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
H
O
HO NO2catalyst 29c
30a 7
31a
solvent, temp.
60 h
entrya catalyst 29c(mol %) solvent temp (°C) yield [%]b ee [%]c
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
5
20
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
THF
THF
THF
toluene
benzene
m-xylene
DCM
diisopropylether
CPME
1,4-Dioxane
Et2O
THP
TFE
ACN
DMA
DMF
DMSO
MeOH
water
neat
0
0
-20
0
0
0
0
0
0
rt
0
0
0
0
0
0
rt
0
rt
0
82
93
70
89
98
95
86
93
86
94
93
trace
94
91
43
57
trace
92
92
96
74
64
78
rac
rac
rac
2
2
rac
55
21
---
rac
53
74
64
---
rac
rac
rac
aThe reaction were carried out with 30a (0.13 mmol), 7 (0.67 mmol) in above mentioned 
dry solvents (2.0 mL). bIsolated yields. cEnantiomeric excess was determined by 
using chiral HPLC on chiralpak AD-H column
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The use of non-polar aromatic solvents also afforded 31a with excellent chemical yields (89-95%), 
but completely in racemic form (entries 4-6).  Furthermore, the reaction in chlorinated and different 
ethereal solvents afforded 31a in good to excellent chemical yields (86-94%) (except THP, in 
which case only trace amount of 31a was formed), but very poor to moderate enantioselectivities 
were observed (entries 7-12). Moreover, the effect of polar solvents such as TFE, ACN, DMA, 
DMF, DMSO and MeOH were also investigated. Unfortunately, satisfactory chemical yields and 
enantioselectivities were not obtained (entries 13-18). The reaction was also conducted in water 
and in neat conditions (nitromethane used as solvent and reactant). Although the product 31a was 
obtained in fairly good chemical yields, good enantioinduction was not observed (entries 19 and 
20). From these results, after screening of catalysts, catalyst loadings, additives, solvents and 
reaction temperatures, author decided to set the conditions as (catalyst 29c (10 mol %), in THF at 
0 °C for 60 h) as optimal conditions for this reaction and started to explore the substrate scope for 
enantioselective nitro-aldol reaction. 
 
2.7.6 Substrate scope for enantioselective nitro-aldol reaction using catalyst 29c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 32. Substrate scope of nitro-aldol reaction using SFAA catalyst 29c 
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In a substrate scope of nitro-aldol reaction, a variety of isatins 30b-k with nitromethane 7 were 
afforded the nitro-aldol products 31b-k in good to excellent chemical yields and moderate to good 
enantioselectivities (Scheme 32). The reactions of N-alkylated isatins such as N-methyl-isatin 30b, 
N-benzyl-isatin 30c and N-allyl-isatin 30d with nitromethane 7 afforded the desired aldol products 
31b-d, respectively, in excellent chemical yields (95-98%) but with low to moderate 
enantioselectivities (26-67% ee). On the other hand, the nitro-aldol reaction using N-Boc isatin 
30e afforded the product 31e in good chemical yield (82%) with excellent enantioselectivity (95% 
ee). 5-Methyl-isatin 30f provided the aldol product 31f in excellent chemical yield (96%) with low 
enantioselectivity (35% ee). Moreover, only trace amount of the aldol product 31g was obtained 
from the reaction of 5-NO2-isatin 30g with 7, although the exact reason was not clear. The use of 
halogenated isatins 30h-k provided the corresponding nitro aldol products 31h-k with fairly good 
to excellent chemical yields (89-97%), but with moderate enantioselectivities (52-64% ee).  
 
2.7.7 Mechanistic investigation of nitromethane and isatin with squaramido unit 
 Finally, the enantioselective reaction mechanistic pathway of this reaction using author 
developed squaramide-fused amino alcohol catalyst 29c was considered based on both the high 
enantiopurity (81% ee) of the chiral aldol product (S)-31a which was obtained from the reaction 
of isatin 30a with nitromethane 7 and the calculation analysis (1: natural bonding orbital (NBO) 
analysis of the hydrogen bonding of simple squaramide I with isatin 30a or nitromethane 7, 2:  the 
hydrogen bonding distance calculations of complexes A or B, 3: electron density of isatin 30a) 
(Figure 10). Thus, (1) NBO analysis was performed subsequently on the optimized structures to 
quantify the donor-acceptor. The stabilization energies (E (2)) of intermolecular interactions of all 
complexes (complexes A and B) were performed by using second order perturbation theory. As 
the calculation result, the stability of A (E(2) / kcal·mol-1 = 1.56) was increased as compared with 
that of B (E(2) / kcal·mol-1 = 0.25). This result might be consistent with the stability of the 
complexes. Furthermore, (2) the hydrogen bonding distance of complex A was also shorter than 
that of complex B. In addition, (3) the place of the highest electron density (Mulliken charge 
distribution) was on oxygen of amide in isatin 30a.  
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Figure 10. (1) The calculated second order perturbation energies (E (2) / kcal, Eamol-1) of the 
second donor (H-bond donor of squaramides) and acceptor (oxygenatoms of isatin 30a and nitrate 
7) interaction for the complexes A and B, (2) the calculated hydrogen bond distances of the 
complexes A and B, (3) The electron density map and Mulliken charge distribution of isatin 30a 
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Scheme 33. Plausible reaction course for nitro-aldol reaction 
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From the mechanistic investigation of isatin 30a and nitromethane 7 with squaramido unit I  
(Figure 12).  A model for the enantioselective nitro-aldol reaction a mechanistic pathway is 
proposed. First, the active methylene proton of nitromethane is abstracted by basic tertiary amino 
group on azepane ring in catalyst 29c to form nitro enolate, which might also induce the strong 
hydrogen bonding interaction between the hydrogen atom of the ammonium moiety on azepane 
ring in catalyst and oxygen atom of nitro enolate. Next, isatin 30a might fixed with catalyst 29c 
through two hydrogen bonds between two carbonyl oxygen atom on isatin 30a and two primary 
amino groups on squaramide site in catalyst. When isatin 30a makes the hydrogen bonding to 
catalyst, one carbonyl oxygen atom of amide on isatin 30a might binds with the hydrogen atom of 
amino group with 3,5-bis(trifluoromethyl)phenyl group as an electron-withdrawing group on 
squaramide site in catalyst and other carbonyl oxygen atom on isatin 30a might binds with the 
hydrogen atom of another amino group on squaramide in catalyst. In addition, the side chain 
containing ammonium alcohol moiety on catalyst might be fixed by the hydrogen bonding 
interaction between hydrogen atom on the hydroxyl group and ammonium moiety on azepane ring 
on the side chain. Among the possible two transition states TS-I and TS-II, TS-II has less steric 
interaction than that of TS-I, which has strong steric repulsion between four membered squaramide 
skeleton and di-phenyl groups on catalyst. Hence the reaction might proceed via the transition state 
TS-II, in which nitroenolate coordinated to ammonium moiety on azepane ring could attack on 
the isatin from the upper side leading to the formation of (S)-31a as major enantiomer, whereas 
minor isomer (R)-31a' might be obtained via the unfavorable transition state TS-I (Scheme 33). 
 
2.8 Summary 
 In summary, author prepared new hybrid type SFAA catalysts 29a-e from commercial 
available amino esters via simple organic transformations and demonstrated their catalytic 
efficiency in the enantioselective nitro-aldol reaction of various isatins 30a-k and nitromethane 7. 
This protocol provides the chiral 3-substituted 3-hydroxyoxindoles 31a-k in excellent chemical 
yields (up to 99%) and excellent enantioselectivities (up to 95% ee). Especially, catalyst 29c 
bearing azepane ring system as basic site showed best catalytic activity for this reaction. The 
obtained 3-alkylsubstituted 3-hydroxyoxindoles could be important intermediates for the synthesis 
of many significant biologically active scaffolds. The feasible mechanistic path of this reaction 
using newly prepared catalyst 29c was also explained by calculated the second order perturbation 
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energies of second donor [H-bond donor of squaramide] and acceptor (oxygen atoms of isatin 30a 
and nitromethane 7) and hydrogen bond distances between catalyst 29c and isatin 30a, and 
nitromethane 7.12 
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Chapter 3 
The New Hybrid Type Squaramide Fused Amino Alcohol 
Organocatalysts For Enantioselective Diels-Alder Reaction of 3-
Hydroxy-2-Pyridones with Maleimides 
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3.1 Introduction  
 The Diels-Alder reaction is a classical organic reaction using with conjugated diene and 
dienophile to form a cyclohexene system, it’s also refered as a [4+2] cycloaddition reaction. The 
DA reaction discovered by Otto Diels and Kurt Alder in 1928 (Scheme 34). For their tremendous 
contribution presented Nobel prize in chemistry in the year of 1950. The Diels-Alder reaction is 
also reliable practical method for constructing the complex bicyclic compounds in synthetic 
organic chemistry.  
  
 
 
 
Scheme 34. General representation of Diels-Alder reaction 
 
The [4+2] cycloaddition reaction usually employs with a diene with electron deficient dienophile, 
in which the diene and dienophile involves an electrocyclic reaction the where diene contributes 
4π-electrons while the dienophile contributes 2π-electrons to afford the cyclohexene framework. 
In the case of an alkynyl dienophile, the initial adduct can still react as a dienophile if not too 
sterically hindered (Scheme 35).31 
 
 
 
 
 
Scheme 35. Diels-Alder reaction using different dienophiles 
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3.1.1 Mechanism of Diels-Alder reaction   
 The mechanism of Diels-Alder reaction obeys concerted pericyclic reaction pathway. The 
reaction follows in a single concerted pathway, during the course of reaction no intermediates are 
formed. In the mechanism of Diels-Alder reaction the electron rich diene reacts with electron 
withdrawing dienophile. Usually it follows [4πS+2πS] cycloaddition, representative that it 
proceeds through the suprafacial-suprafacial interactions of a 4π-electron system of the diene with 
a 2π-electron system of dienophile, an interaction that is thermally allowed called as [4n+2] 
cycloaddition (Figure 11). 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 11. Pictorial representations of frontier molecular orbitals of Diels-Alder reactions 
 
In a normal electron-demand DA reaction predominately occurs between electron rich dienes and 
electron deficient dienophiles, while in the case of inverse electron demand DA reaction is 
controlled by electron withdrawing dienes with electron rich dienophiles to afford the DA 
adducts.32 
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3.1.2 Regioselectivity of Diels-Alder reaction 
 The frontier molecular orbital (FMO) analysis is used to explain the regioselectivity 
outlines in Diels-Alder reactions. The diene and dienophile resonance effects can be taken in 
consideration to assume the regioselectivity of the DA reaction. The figure depicted below shows 
the partial moment of resonance charges in a diene creates more electron density towards electron 
donating group. In the case of dienophile, the partial resonance charges moment is towards electron 
withdrawing group, by these phenomena of resonance effects in diene and dienophiles it’s easy to 
predict the regioselectivities of DA reaction (Figure 12).  
 
 
 
 
 
Figure 12. Diene, dienophile charge distribution 
 
In a normal-demand DA reaction, the diene is bearing with an electron donating group at C1 
position takes its major HOMO amount at C4, although the dienophile has the largest LUMO 
factor at C2 combination of these factors affords the “ortho” product A. The diene containing at 
C2 position as in case of B underneath has the more HOMO factor at C1, which allows the “para” 
adduct. Parallel approach for the equivalent inverse-demand DA reaction takes place which gives 
rice to related adduct depicted as C and D (Scheme 36). 
 
 
 
 
 
Scheme 36. Regioselectivity in Diels-Alder reaction 
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3.1.3 Stereoselectivity in Diels-Alder reaction 
 The Diels-Alder (DA) reaction are concerted cycloaddition reactions i.e. the 
stereochemistry of the reactants which involves in DA reaction as retains in their corresponding 
products. For example, the DA reaction of cyclopentadiene with dimethyl fumarate affords two 
different products, the endo and exo, might conceivably be formed depending on the manner in 
which the diene and dienophile are disposed in the transition state. According to the endo addition 
rule, in diene addition reaction two components arrange themselves in parallel planes. The afforded 
bicyclic products as two isomers endo (74% yield) along with exo (26% yield) isomers is depicted 
in following reaction. In a similar manner the DA reaction of trans-1,4-butadiene with maleic 
anhydride produces two unequal amounts of trans and cis isomers in the course of DA reaction. 
In this reaction the stereochemistry of the butadiene retains in the trans DA adduct as major 
product (Scheme 37).33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 37. General representation of stereoselectivity in Diels-Alder reaction 
 
3.1.4 The diene 
 The well explored dienes in DA reaction consists 1-methoxy-3-trimethylsiloxy-1,3-
butadiene moiety, it’s also referred as Danishefskys diene E, it has precise synthetic value for 
providing unsaturated 1,2-cyclohexenone systems. Additionally, the Brassard developed 1,3-
alkoxy-1-trimethylsiloxy-1,3-butadienes F, and Rawal explored 1-dialkylamino-3-
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unsaturated systems (dienes) with appropriate dienophiles provides synthetically valuable 
complex motifs in the synthetic organic chemistry (Figure 13).34 
 
 
 
 
 
Figure 13. Most investigated dienes in Diels-Alder reaction 
 
Most of the unstable o-quinodimethanes dienes usually generated by in-situ in the course of the 
DA reaction at elevated reaction temperature. For generating o-quinodimethanes reactive species 
pyrolysis method usually employed. For example, the benzocyclobutenes, benzosulfones, 1,4-
elimination of ortho- benzylic silanes, and sulfonyls, produces the unstable o-quinodimethanes 
diene reactive species at high reaction temperatures and which can easily participate in the DA 
reactions. Additionally, the reduction of a,a'-ortho benzylic dibromides results in the formation 
of unstable dienes (Scheme 38). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 38. In-situ generation unstable O-quinodimethanes dienes  
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ketones, vinyl sulfones, allenes, thioketones, nitroso-benzene and electron withdrawing 
carboxylates.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Different types of dienophiles that undergo Diels-Alder reaction 
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3.1.7 Intramolecular hetero Diels-Alder (IMHDA) reaction 
 The intramolecular hetero-Diels-Alder (IMHDA) reaction is useful synthetic protocol in 
synthetic organic chemistry,
 
it is an adaptable protocol for the synthesis of novel polycyclic 
systems. By using this protocol, it is easy to construct the natural products and biologically active 
compounds. Recently, Corey and Nicolaou36 has applied the IMHDA protocol to synthesis   
macrocyclic dilactone family alkaloid such as, (+)-carpine and (+)-azimine, these natural products 
are constructed using, the acylnitroso-DA (IMHDA) protocol (Scheme 39). The synthesis began 
with optically active (S)-1,2,4-butanetriol 32 as starting material. After the successive synthesis of 
the compound 33 from 32 its reacted with NaIO4 to afford the compound 34 which was underwent 
IMHDA reaction to afford the DA-adducts 35 and 36 as diastereomers. Among them the major 
diastereomer 35 was applied for the total synthesis of (+)-azimine 37 and (+)-carpine 38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 39. Importance of hetero Diels-Alder reaction in (+)-azimine and (+)-carpine synthesis 
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3.1.8 Intermolecular aza-Diels-Alder reaction 
 The catalytic enantioselective intramolecular aza-Diels-Alder reaction is remains most 
adorable protocol for synthesizing many natural products. The aza-Diels-Alder reaction transforms 
imines and dienes into a biologically active tetrahydropyridines. The significance of the aza-Diels-
Alder reaction is for the construction of a six-membered ring containing nitrogen functional. 
Recently, Jacobson and his research group37 reported the total synthesis of (+)-Reserpine by 
employing an aza Diels-Alder reaction strategy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 40. Importance of aza-Diels-Alder reaction in (+)-reserpine synthesis 
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A highly diastereoselective catalyst-controlled aza-Diels-Alder reaction between imine 39 and α-
substituted enone 40 were observed in the presence of chiral amino organocatalyst 41 providing 
the desired DA-adduct 42. The obtained DA-adduct can undergo oxidation in the presence of Dess-
Martin periodinane to afford the aldehyde 43. Further, the compound 43 was cyclized in the 
presence of piperidine and p-TsOH in toluene to afford compound 44 with 86% yield. Additional 
manipulation of compound 44 involving aldehyde oxidation/esterification, elimination/reduction 
of alcohol, de-protection of PMB ether and tosyl amine, and installation of the trimethoxybenzoyl 
(TMB) ester which led to the formation of targeted (+)-reserpine 45 (Scheme 40). 
 
3.1.9 Oxo-Diels-Alder reaction 
 The oxo-Diels-Alder reaction usually employs of methyl pentadiene with formaldehyde to 
afford the dihydropyran ring systems. The oxo-Diels-Alder reaction was first reported in 1949 
using a methyl pentadiene with formaldehyde (Scheme 41).38b 
 
  
 
Scheme 41. Oxo-Diels-Alder reaction 
 
 M. S. Sigman and his research group38a reported the enantioselective oxo-Diels-Alder 
reaction using oxazoline 48 based hydrogen bond catalyst. They developed the new elegance of 
segmental oxazoline catalysts that trigger aldehydes 47 via hydrogen bond formation. The 
activated aldehydes can participate in highly enantioselective oxo-Diels-Alder reaction with diene 
46 (Scheme 42).  
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Scheme 42. Importance of oxo-Diels-Alder reaction for chiral dihydro-pyrans  
 
3.1.10 Thio-Diels-Alder reaction 
 Recently K. A. Jørgensen and his research group39 reported a enantioenriched sulfur-based 
heterocycles by TMS prolinol organocatalyst 52. The catalytic enantioselective Diels-Alder 
reaction of dienal 50 with dithioester 51 affords the corresponding chiral dihydrothiopyrans 53 in 
both good chemical yields (up to 89%) and enantioselectivities (up to 92% ee) (Scheme 43).  
 
 
  
 
 
 
Scheme 43. The oxo-Diels-Alder reaction to synthesis of chiral dihydrothiopyrans  
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successfully converted in to TBS protected chiral piperidines 58 which upon de-protection in the 
presence of TBAF afforded the optically aactive chiral piperidine 59 having four continuous 
stereogenic-centers (Scheme 44). 
 
 
 
 
 
Scheme 44. b-Amino alcohol organocatalyst catalyzed enantioselective Diels-Alder reaction 
 
3.2 Base catalyzed Diels-Alder reactions 
 Y. Yamamoto and his research group40 reported the enantioselective base catalyzed Diels-
Alder reaction of anthrone 60 with 2-tert-butyl-phenylmaleimide 61 using pyrrolidine derivative as 
basic organocatalysts 62. They obtained the corresponding DA-adduct 63 in excellent chemical yield 
(up to 97%) and with good enantioselectivities (up to 87%) (Scheme 45).    
 
  
 
 
 
Scheme 45. The base catalyzed Diels-Alder reaction of anthrone with 2-tert-butyl-phenyl maleimide 
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 H. Okamura and his research group41 reported the enantioselective base catalyzed Diels-
Alder reaction of 3-hydroxy-2-pyrone 64 with optically active acrylate 65 using with catalyst 66, to 
afford DA-adduct 67 with >95% de. They also demonstrated the synthetic utility of obtained DA-
adduct for synthesizing (-)-theobroxide 68 (Scheme 46). 
 
 
 
 
 
Scheme 46. The base catalyzed Diels-Alder reaction of 3-hydroxy-2-pyrone with acrylate 
 D. W. C Macmillan and his research group42 reported the enantioselective Diels-Alder 
reaction using secondary amine imidazolidinone basic catalyst 71 of tryptamine 69 with enal 70 via 
iminium pathway. Which afforded the structurally complex DA-adduct 72 in moderate yields (up to 
70%) and in excellent enantioselectivities (up to 95%). The obtained DA-adduct 72 was successfully 
applied in the total synthesis (-)-vincorine 73 natural product using Diels-Alder/amine cyclization 
cascade reaction strategy (Scheme 47). 
 
 
Scheme 47. The base catalyzed Diels-Alder reaction of tryptamine with enal 
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 W. Yang and his research group43 reported the enantioselective Diels-Alder reaction of 
enal 74 with diene 75 using catalyst 76 to afford the DA-adduct 77 in good chemical yield (up to 
88%) and in excellent enantioselectivities (up to 98%). And also, they demonstrated the synthetic 
utility of obtained DA-adduct 77 for the total synthesis of (+)-propindilactone G 78 (Scheme 48). 
 
 
 
 
Scheme 48. The base catalyzed Diels-Alder reaction of enal with diene 
 
3.3 Previous reports on enantioselective Diels-Alder reaction of 3-hydroxy-2-pyridones with 
electron withdrawing dienophiles.  
 H. Okamura and his research group41a reported base catalyzed Diels-Alder reaction of 3-
hydroxy-2-pyridones 79 with dienophiles 80 using triethyamine as base, to afford 4-
hydroxyisoquinuclidines 81 and 82 with 76% yield (Scheme 49). 
 
 
 
Scheme 49. The base catalyzed Diels-Alder reaction of 3-hydroxy-2-pyridones with dienophiles 
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indanol catalysts 85a-d, among the optimized catalysts, the catalyst 85a have showed the best 
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(up to 97% yield) and enantioselectivities (up to 96% ee) (Scheme 50).  
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Scheme 50. Enantioselective Diels-Alder reactions of 3-hydroxy-2-pyridones with maleimides 
using amino-indanol organocatalysts 
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  Recently from author research group reported the simple primary b-amino alcohol45 
catalyzed Diels-Alder reaction of 3-hydroxy-2-pyridones 87 as dienes with N-substituted 
maleimides 88 as dienophiles to afford the highly substituted optically active isoquinuclidines 90 
as a single diastereomers in excellent enantioselectivities (up to 98%) with excellent chemical 
yields (up to 95%). In this study, a range of simple b-amino alcohols 89a-i were synthesized from 
the corresponding inexpensive amino acids and their catalytic activity was examined for this 
reaction. Among them, catalyst 89a was found to be best catalyst for affording the chiral 4-
hydroxyisoquinuclidines (Scheme 51). 
 
 
 
 
 
Scheme 51. b-amino alcohol oraganocatalyzed Diels-Alder reaction of 3-hydroxy-2-pyridone with     
maleimides 
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3.4 Author strategy 
 Author aimed to develop the simple primary b-amino alcohol X and their derivatives as a 
new class of organocatalysts, since they are easy to synthesize, stable on exposure to air, an 
inexpensive alternative to the other primary amino organocatalysts such as a chiral diamines and 
cinchona derived primary amines (Figure 15). Most recently, author successfully developed the 
new hybrid type squaramide fused aminoalcohol (SFAA) Y and revealed the utility as the 
organocatalyst in the enantioselective nitro-aldol reaction of nitroalkanes with isatins to afford 
chiral 3-alkyl-3-hydroxyoxindoles, which is useful intermediate for biologically active 
compounds. The Diels-Alder (DA) reaction using 3-hydroxy-2-pyridones 91 as dienes in the 
presence of dienophiles using SFAA organocatalysts provides synthetically valuable 
multifunctional chiral 4-hydroxy-isoquinuclidines 92. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Functionality of squaramide fused amino alcohol (SFAA) organocatalysts 
 
The obtained isoquinuclidines can be easily access to the many biological active compounds such 
as oseltamivir (Tamiflu) 93 to prevent both influenza A and B virus. Furthermore, DA adduct also 
plays key precursors for the synthesis of ibogaine 94 which is a naturally occurring psychoactive 
compound and anticancer drug. And also, isoquinuclidines are the primitive intermediates for 
synthesis of vinblastine 95a and vincristine 95b natural products, these natural products play key 
role in chemotherapy medication (Scheme 52).  
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Scheme 52. Synthetic utilities of 4-hydroxyisoquinuclidines 
 
3.4.1 Results and discussions 
 To further expand the efficiency of SFAA as an organocatalyst, author tried the DA 
reaction of 3-hydroxy-2-pyridones with dienophiles using chiral SFAA organocatalyst. As a 
concept of the expression of enantioselectivity in this reaction using SFAA catalyst, the reaction 
might be proceeding through a transition state A, in which the anionic oxygen at 3-position on the 
pyridones might be fixed by the hydrogen bonding interactions with the ammonium site on catalyst 
(Scheme 53). Furthermore, the amide oxygen atom of pyridones might be fixed by the hydrogen 
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synthetic precursors for the synthesis of several natural products that have a broad spectrum of 
fascinating biologically activities. 
 
 
Scheme 53. Concept of SFAA orgaanocatlysts for Diels-Alder reaction 
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3.4.2 Enantioselective Diels-Alder reaction using catalysts 29a-e 
 First, author examined the catalytic ability of SFAA catalysts 29a-e in the DA reactions of 
common 3-hydroxy-1-tosyl-2-pyridone 96a and N-phenylmaleimide 97a in DCM as a solvent at 
0°C (entries 1-5, Table 4).  All reactions using catalysts 29a-e, which were easily prepared by 
author previous reported method, afforded the endo-DA adduct [1R,4R]-98a as a major isomer. 
 
Table 4. Enantioselective DA reaction using catalysts 29a-e 
 
 
 
 
  
 
 
 
The catalyst 29a having a basic pyrrolidine ring at side chain showed a good catalytic activity and 
afforded the DA adduct 98a with good chemical yield and moderate enantioselectivity (87%, 64% 
ee, entry 1). However, both catalysts, 29b having piperidine ring and 29c having azepane ring, at 
side chain gave 98a with low enantioselectivities, although chemical yields were fairly good 
(entries 2,3). Furthermore, catalyst 29d having morpholine ring or catalyst 29e having 
thiomorpholine ring at side chain did not show satisfactory catalytic activities in this reaction 
conditions (entries 4,5). In addition, the reaction using superior catalyst 29a also tried at low 
temperatures (-20°C and -80°C). Although expecting enantioselectivity were not afford anymore, 
chemical yields were moderate (entries 6,7). From the above results, author revealed that catalyst 
29a having five membered pyrrolidine ring system as a Brønsted basic site at side chain is better 
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for obtaining satisfactory results for chemical yield and enantioselectivity.    
3.4.3 Optimization of DA reaction conditions using catalyst 29a 
 In order to optimize the reaction conditions using the superior catalyst 29a, author next 
examined the effect of the molar ratio of catalyst 29a, the effect of solvent and reaction time (Table 
5). The decrease of catalytic loading of 29a to 5 mol% resulted in a slight decrease in the chemical 
yield (50%) and a substantial decrease the enantioselectivity (42% ee) (entry 1). The increase of 
catalytic loading of 29a to 20 mol% resulted in a slight increase in the chemical yield (90%), but 
enantioselectivity was decreased to 32% ee (entry 2) than that of the reaction containing 10 mol% 
of 29a (entry 1, Table 5), although the reason is not clear. To further improve the enantioselectivity, 
author also examined the solvent effects on this reaction. Commonly used aprotic nonpolar 
(CHCl3, ClCH2CH2Cl, MTBE, Et2O, THF, 1,4-dioxane, toluene, PhCl, xylene) and polar protic 
(MeOH) solvents were screened, respectively (entries 3-12). The endo-[1R,4R]-98a were obtained 
in all solvents with moderate to good chemical yields (62-92%), but enantioselectivity were poor 
to low (2-42% ee, entries 3-12). Unfortunately, no improvements in enantioselectivity were 
observed in these solvents in comparison with the use of CH2Cl2 (entry 1, Table 5). Under the best 
reaction conditions (DCM, 29a: 10 mol%, 0°C), the reaction time was extended to 48 h and 96 h, 
respectively, led to an increase in the chemical yields, although the satisfactory enantioselectivities 
were not observed in both reaction times (entries 13,14). From these results, author clarified that 
the use of 10 mol% of catalyst, 0°C of the reaction temperature, and 24 h of reaction time is the 
best reaction conditions. 
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Table 5. Optimization of DA reaction using catalyst 29a 
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3.4.4 Substrate scope for enantioselective DA reaction using catalyst 29a 
 Under the optimized reaction conditions, wide ranges of the DA reaction with 2-pyridones 
96a,b and maleimides 97b-k were investigated using superior catalyst 29a to afford the 
corresponding endo-DA adducts 98b-k and the results are shown in Table 6. First, the reaction of 
2-pyridone 96a with several maleimides 97a-i using catalyst 29a (10 mol%) were examined under 
optimized reaction condition (DCM, 0°C, 24 h), respectively. The use of N-methylmaleimide 97b 
afforded the corresponding DA adduct 98b in an excellent chemical yield (96%), although the 
enantioselectivity was low (22% ee) (entry 1). The use of N-ethylmaleimide 97c also afforded 98c 
in a fairly good chemical yield (90%) and the enantioselectivity also slightly increased to 25% ee 
(entry 2). Moreover, the reaction of 96a with maleimides 97d-i having electron-donating or 
electron-withdrawing groups at 4-position on phenyl group. 
 
Table 6. Substrate scope for DA reaction of pyridones using catalyst 29a 
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Additionally, N-(4-methylphenyl)maleimide 97d did not afford the corresponding DA adduct 98d  
in a satisfactorily enantioselectivity (20% ee), although the chemical yield was fairly good (90%) 
(entry 3). The reaction with N-(4-nitrophenyl)maleimide 97e having a strong electron-withdrawing 
nitro group at 4-position on phenyl group was not proceed to obtained the endo-98e, why the 
reason is not clear (entry 4). Furthermore, the use of maleimides 97f-i having halogeno group at 
4-position on phenyl group afforded the corresponding DA adducts 98f-i in good chemical yields 
(78-92% ee), but satisfactory enantioselectivities were not obtained (34-42% ee) (entries 5-8) in 
the optimized reaction conditions. Author also examined the DA reaction of more steric hindered 
3-hydroxy-1-(2,4,6-trimethylphenylsulfonyl)-2-pyridone 96b with maleimides 97j,k respectively. 
However, contrary to expectation, the desired endo-DA adducts 98j,k did not obtained with 
satisfactorily enantioselectivity (98j: 22% ee, 98k: 39% ee) (entries 9, 10), but, the chemical yields 
were sufficient (98j: 92%, 98k: 95%) similar to most of used maleimide dienophiles 97a-d,f-i. 
 
3.4.5 Enantioselective DA reaction of substituted pyridones using catalyst 29a 
 Author next evaluated the asymmetric DA reactions of 4-halogenated or bulky alkylated 
3-hydroxy-2-pyridones 99a-d with maleimides 100a-f using catalyst 29a (10 mol%) at the 
optimized reaction conditions (DCM, 0°C, 24 h) (Table 7).  
 
Table 7. Substrate scope for DA reaction of substituted pyridones using catalyst 29a 
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using Chiralpak AS-H and chiralcel OD-H columns. dThe aboslute configuration of 
101a was determined by X-ray.
 65 
First, author tried the reaction using 2-pyridones 99a-d having halogeno group at 4-position on 
pyridone ring. The enantioselective were observed to increase in all reactions with corresponding 
endo-DA adducts 101a-f moderate to excellent enantioselectivities (64-98% ee) and in excellent 
chemical yields (89-95%, entries 1-6). In particular, a dramatic increase in enantioselectivity (98% 
ee, entry 1) was observed in the reaction of 4-brominated-2-pyridone 99a with 100a to afford the 
DA adduct (1R,4S)-101a, which has the opposite absolute configuration in comparison with DA 
adduct (1R,4R)-101a obtained from the reaction of 99a with 100a (entry 1, Table 7). The absolute 
stereochemistry of [1R,4S]-101a was determined by X-ray analysis (Figure 16).  And also, an 
improvement of enantioselectivity was conformed in the reactions using 2-pyridones having allyl 
and propyl functional groups at 4-position on pyridone ring (entries 5, 6). Although the reactions 
afforded the corresponding DA adducts 101e,f with high chemical yields, the enantioselectivity 
were moderate to good (101e: 93%, 74% ee, 101f: 90%, 50% ee) (entries 5, 6). From these results, 
it might be indicated that the steric influence of substituent group at 4-position on pyridone ring 
might participate to fix the direction of diene in the transition state for increasing of 
enantioselectivity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Absolute stereochemistry of DA-adduct 101a by X-ray analysis 
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3.4.6 Plausible reaction course of the 3-hydroxy-2-pyridone 96a with N-phenyl maleimide 
97a using catalyst 29a. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 54. Plausible reaction course of pyridone 96a with N-phenyl maleimide 97a using catalyst      
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Based on the both observed enantiopurities (98a: 64% ee, entry 1, Table 4; 101a: 98% ee, entry 1, 
Table 7) of chiral DA adducts 98a or 101a that were obtained from the reactions of 96a with 97a 
or 99a with 100a, and site of the highest electron density (Mulliken charge distribution) in 96a and 
99a the following enantioselective reaction mechanism were proposed (Schemes 54 and 55). First, 
the reaction with 96a might proceed through the more stable transition state Ts-2 than Ts-1 to 
afford [1R,4R]-98a. Thus, 3-hydroxy-2-pyridone 96a might be fixed with catalyst 29a through the 
hydrogen bonding interactions of both between the amide oxygen atom of 96a and the two primary 
amino hydrogen atoms on the squaramide part of 29a and between the hydrogen atom of the 
ammonium moiety on the pyrrolidine ring of 29a and the anionic oxygen atom at 3-position of 96a 
(intermediate: I-A). Then, when dienophile 97a attacks on pyridone moiety, the reaction might 
proceed through the upper face of anionic pyridone coordinated to catalyst in the transition state 
(Ts-2) that has less steric interactions between the diamino alcohol part on catalyst 29a and 96a 
than that of Ts-1 that has more steric interactions (Scheme 54).  
 
3.4.7 Plausible reaction course of the reaction of 4-bromoro-3-hydroxy-2-pyridone 99a with 
with maleimide 100a using catalyst 29a. 
  On the other hand, the reaction of 99a with 100a affording [1R,4S]-101a might proceed 
through Ts-4 than Ts-3  (Scheme 55), based on three facts (a)-(c): (a) the reaction proceeded with 
a high enantioselectivity (98% ee), (b) the obtained DA adduct 101a has an opposite absolute 
stereochemistry in comparison with the DA adduct 98a obtained from the reactions using 96a and 
97a, and (c) the site of the highest electron density (Mulliken charge distribution) of 99a was on 
the oxygen atom of the amide moiety. Thus, the hydroxyl proton is abstracted from 99a by the 
basic tertiary amino group of the pyrrolidine ring of 29a to form intermediates B or C, which might 
be fixed by two places of hydrogen bonding interactions both between the hydrogen atom of the 
ammonium moiety of the pyrrolidine ring of 29a and the anionic oxygen atom at 3-position of 99a 
and between two primary amino hydrogen on the squaramide part of 29a and the amide oxygen 
atom of 29a. In the intermediates I-B or I-C, the intermediate I-B might be more advantageous 
than I-A that has larger steric interactions between the bromine atom on pyridone and the 
pyrrolidine ring of catalyst. And then, the reaction with dienophle 100a might proceed through the 
transition state Ts-4 that has less steric interactions between the catalyst part and 99a than Ts-3 
that has more steric interactions (Scheme 55). 
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Scheme 55. Plausible reaction course of 4-bromo-3-hydroxy-2-pyridone 99a with N-phenyl 
maleimide 97a using catalyst 29a 
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3.5 Summary 
 Author demonstrated that new hybrid type squaramide fused aminoalcohol (SFAA) 29a 
containing both Brønsted basic site and hydrogen bonding site in the molecule showed highly 
catalytic activity as an organocatalyst in the enantioselective Diels-Alder reaction of 3-hydroxy-
2-pyridones 96a,b and 99a-d with maleimides 97a-k, 100a-f with excellent chemical yields and 
enantioselectivities (up to 95%, up to 98% ee).46 Particularly, the reaction of 4-brominated 2-
pyridone 99a with maleimides 97a afforded the corresponding 4-hydroxyisoquinuclidines 101a in 
both excellent chemical yield and enantioselectivity (95%, 98% ee) having an opposite absolute 
stereochemistry in comparison with the DA adduct 98a from the reactions using common 3-
hydroxy-2-pyridone 96a. 
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Chapter 4 
The New Hybrid Type Squaramide Fused Amino Alcohol 
Organocatalysts For Enantioselective Domino Michael Addition 
Cyclization Reaction 
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4.1. Introduction 
 The class of 2-amino-pyrans has been known for several decades. The first representative’s 
pyranopyrazole A and pyranopyranone B are from the late 1950s to the early 1960s. Spiro-
conjugated pyranopyrazole A was obtained in studies on pyrazolone dyestuffs, while 
pyranopyranone B served as a precursor for the blood anticoagulant warfarin (Figure 17). 
 
 
 
 
Figure 17. The first representatives of 2-aminopyrans 
 
The formation of the pyran ring, bearing an amino group in 2-position, tends to be reversible. The 
presence of a strong electron-withdrawing substituent in 3-position (e.g., CN, COR, CO2R) seems 
to be crucial for the stability of these compounds. Since the middle 1970s there has been rapid 
progress in the chemistry of 2-amino-4H-pyrans, studies on their physicochemical properties, as 
well as various types of biological activity. In recent years, modern techniques were applied to 
aminopyran synthesis, such as, catalytic electro generation, microwave and ultra-sonic assistance, 
the use of “green” solvents, and solid-phase synthesis. Reviving interest in 2-aminopyrans can be 
attributed to the discovery of new types of biological activity compounds.47 
 
4.1.1 Appearance 
 Most of the 2-amino-pyrans are colorless, pale-yellow, or pale-cream crystals with high 
melting points. They are readily soluble in aromatic hydrocarbons, alcohols, acetone, acetonitrile, 
chloroform, DMF, and DMSO, and nearly insoluble in hexane and water.  
 
4.1.2 UV spectroscopy of 2-aminopyrans 
 UV spectroscopy is used as a supplementary method for characterization of 2-aminopyrans 
and most correspond to π-π* and π-n electron transfers of C=C-O and C=C-N fragments, as well 
as to π-π* transfers of aryl substituents. Compound C 13 reveal a single absorption maximum at 
296-305 nm, more recently at 206, 243, and 297 nm (when X = CN), and 208, 265, and 298 nm 
(when = COOMe). Signal maxima at 225-230 nm characterize 2-aminopyrans, while the 
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tetrahydrochromene D shows maxima at 220 and 269 nm (Figure 18).48 
 
 
 
 
 
Figure 18. Prominent functional groups of 2-aminopyrans in UV spectroscopy 
 
4.1.3 IR spectroscopy of 2-aminopyrans 
 Stretching vibrations of an -NH2 group 3450-3200 cm-1 are always present in IR spectra of 
2-aminopyrans. special analysis of IR and Raman spectra on a series of non-annulated pyrans has 
been carried out. One or several bands in the 1650-1590 cm-1 region, attributed to bending 
vibrations of -NH2 and stretching vibrations of C=C, are also characterstics for aminopyrans. More 
propably, these bands correspond to the superposition of d (NH2) and v (C=C) vibrations. A general 
feature of 3-cyanopyrans is the presence of a highly intense stretching band of the -CN group 
(2205-2180 cm-1). The very high intensity and low-frequency shift possibly can be connected with 
a developed system of electron π-π-conjugation in an enamino nitrile moiety. Notably, starting and 
intermediate nitriles used in the synthesis of 2-amino-3-cyanopyrans E show moderate to weak 
nitrile group absorption at 2260–2220 cm-1 nitrile band is very characteristic (Figure 19). 
 
 
 
Figure 19. Characteristic vibrations of amine and nitrile functional groups in IR spectroscopy 
 
4.1.4 NMR spectroscopy of 2-aminopyrans 
 NMR spectroscopy is the main method for characterization of 2-amino-4H-pyrans. Most 
1H NMR data were obtained using DMSO-d6 and CDCl3. The spectra always contain a signal for 
NH2 protons (br. s, 2H), but its chemical shift strongly depends on the nature of a 3-substituent 
and conditions. The majority of known 2-aminopyrans contain a single alkyl or aryl substituent 
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R1. So 4H reveals its very characteristic signal at 4.10-4.60 ppm. When R1 is an aryl group with 
strong electron-withdrawing substituent in o- or m-positions, the 4H proton singlet shifts downfield 
to 4.50–5.50 ppm. When R1 is 2-O2NC6H4, a weak intramolecular hydrogen bond forms. A small 
series of 6-unsubstituted 2-aminopyrans reveal an H(6) peak in the region 7.15-7.91ppm in 
DMSO-d6 (Figure 20).48b 
 
 
 
 
Figure 20. Prominent 1HNMR signals of 2-aminopyrans 
4.1.5 Methods of synthesis 
 The most widely known 2-aminopyrans contain a primary amino group, generalized in 
(Scheme 56).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 56. General method of 2-aminopyran synthesis 
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The general synthetic approach involves cyclization of Michael adducts 104 via nucleophilic 
addition of an enolic oxygen 102 to a nitrile group 103 and subsequent tautomeric shift of the 
resultant 2-iminopyran 105 to 2-aminopyran 106.49 
 
4.2 Synthesis of spiro-conjugated 2-aminopyrans 
 In contrast to acyclic monoketones, which usually do not form aminopyrans, reactions of 
cyclic ketones or their cyanomethylene derivatives with methylene-active carbonyl compounds 
gives spiro-conjugated 2-aminopyrans. Their syntheses are represented by fewer examples 
relatively to 4-arylpyrans, but many them latter draw attention due to their promising biological 
activities. The first example of reaction of 3-cyanomethyleneindol-2-one 107 with 1,3-
dicarbonylcompounds 108 results in the formation of a series of spiro-annulated pyrans 109 
(Scheme 57). The tert-butylacetoacetate also reacts with 3-(dicyanomethylene)-indo-2-one 110 in 
the similar manner. Acetone and acetophenone 111 undergo Michael addition toward, but adducts 
112 do not cyclize into pyrans due to their relatively low degree of enolization. On reduction of 
the latter adduct 113 by sodium borohydride, the -OH group thus formed immediately attacks the 
nitrile group with cyclization into 5,6-dihydropyrans 114.49c 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 57. Synthesis of spiro-annulated and 5,6-dihydropyrans 
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4.2.1 Synthesis of dispiro-dipyrano-benzoquinones 
 The synthesis of dispiro-dipyrano compounds is an important challenge, weather both ring 
contributing to its structure is unique identical, or whether they are carbocyclic or heterocyclic-
owing the practical implications of tetra-functionalizing the center spiro atoms. spiropyran is type 
of organic compounds known for photochromic properties that provides this molecules ability’s 
for being used in the field of medical and material sciences. Spiro-pyrans usually possess a 
photochromic property’s, photochromic is a property which forms a change of color in a material 
by incident radiation. The A. K. El-shafei and his research group50 developed the synthesis of 
dispiro-dipyrano-benzoquinones from the starting material of bis-dithiolobenzoquinone 115 which 
upon reaction with piperdine in the presence of ethanol at elevated temperatures afford the 
oxopropylidene-bis-dithilo-benzoquinone compound 116, which upon further condensation with 
malononitrile afford the Michael adduct 117, which undergoes the cyclization give the mixture of 
products of dispiro-dipyrano-benzoquinone 118 and 119 (Scheme 58). The spiro-pyrans plays a 
key role in photochromic, thermochromics, solvatochromic, and electrochromic properties makes 
them especially important in field of technological. Nowadays the spiro-pyrans are most used as 
molecular logic devise, photochromic and electro optical devices. 
 
 
 
 
 
 
Scheme 58. Synthesis of dispiro-dipyrano-benzoquinones 
 
4.2.2 Synthesis of cyclophan 2-aminopyrans 
 A cyclophane is a hydrocarbon consisting of an aromatic unit and an aliphatic chain that 
forms a bridge between two non-adjacent positions of the aromatic ring. More than 50 years after 
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ongoing research. The investigation of their physical and stereochemical properties were attractive 
point of the [2n]cyclophanes in organic chemistry. Undoubtedly, research with future generation 
of cyclophanes will continue to contribute some of the most fascinating developments in the field 
of supramolecular chemistry. The A. A. Aly and his research group51 were developed the first 
synthesis of spiro-pyranoindanoparacyclophanes 123. In which the carbonyl [2.2]paracyclophane 
compound was condensed with malononitrile in basic medium to afford the compound 121, the 
compound later allowed to reacted with acetonyl acetone or keto-esters 122 to afford the cyclophan 
2-aminopyrans 123 with good to moderate chemical yields (Scheme 59). 
 
 
 
 
 
 
Scheme 59. Modular synthesis of spiro-pyanoindanoparacyclo-phanes 
 
 
4.2.3 Synthesis of spiro-homophthalimidepyrans 
 The H. Otomasu and his research group52 reported the spiro-homophthalimide pyrans 
(scheme 60). Their preparation started with the oxohomophthalimide 124 with malononitrile in the 
presence of basic medium will give the knoevenagel adduct 125 which further reacts with acetyl 
acetones or keto-esters which led to the formation of desired spiro-pyrans 126. In the same way, 
the N-heterocyclic oxindole 127 when reacted with 1,3-carbonyl compounds such as acetylacetone 
or keto-esters led to formation of carbocyclic spiropyrans 128. The spiro-homophthalimidepyrans 
possess a structural feature with an -CO-N-(R)-CO and an imide ring these feautures help them to 
be biologically active and pharmaceutically useful motifs. The structural diversity and biological 
importance of nitrogen containing heterocycles have made them attractive targets for synthesis 
over many years. Among them the spiro-homophthalimidepyrans in organic chemistry, imide is a 
functional group consisting of two carbonyl groups bound to nitrogen. They are hydrophobic and 
neutral, and can therefore cross biological membranes in vivo. These compounds are structurally 
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related to acid anhydrides. The spiro-homophthalimidepyrans have received attention due to their 
androgen receptor antagonists, anticonvulsant, antimicrobial, hypoglycemic, anti HIV-1 activities. 
  
 
 
 
 
 
 
 
 
 
 
 
Scheme 60. Synthesis of spiro-homophthalimidepyrans 
 
4.2.4 Synthesis of spiro-benzothiazolepyrans 
 The spiro-benzothiazole belongs to the family of bicyclic heterocyclic compounds having 
benzene nucleus fused with five-membered ring comprising nitrogen and sulfur atoms. spiro-
benzothiazole is an important scaffold with a wide array of interesting biological activities and 
therapeutic functions including antitubercular, antimicrobial, antimalarial, anticonvulsant, 
anthelmintic, analgesic, antiinflammatory, antidiabetic and antitumor activities. A. K. El-shafei 
and his research group53 were reported the spiro-benzothiazolepyrans 132 from diacylated 
benzothiazole 129 as a starting material which upon reaction with sodium methoxide in polar 
protic solvents afforded the mono acylated benzothiazole compound 130 which upon condensed 
with malononitrile to afford the Michael adduct 131 which underwent cyclization to afford the 
spiro-benzothiazolepyrans 132 (Scheme 61).  
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Scheme 61. Synthesis of spiro-benzothiazolepyrans 
4.3 Chemical properties of 2-aminopyrans 
 The reactivity of 2-amino-4H-pyrans as well as their chemical properties has been poorly 
studied because of their weak stability toward many reactants. They undergo ring opening and re-
cyclization in the presence of strong acids and bases, nucleophiles, and so on. But this feature can 
be turned to advantage in the synthesis of various heterocycles via re-cyclization. Thus, the 
enamino moiety in 2-amino-4H-pyran-3-carbonitriles and 2-amino-4H-pyran-3-carboxylic esters 
provides access to diverse derivatives, including fused pyrans. The available data on the chemical 
properties of 2-aminopyrans are not systematic, and, in certain cases, are contradictory.  
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4.3.1 Photochemical contraction of pyran ring 
 The Photochemical contraction of pyran ring in 2-aminopyrans 133 leads to the formation 
of mixtures of cyclobutenes 134, not easily accessible, accompanied with olefins 135 and alkynes 
136.  
 
 
 
 
 
 
 
 
 
 
Scheme 62. Photochemical contraction of aminopyrans 
A mechanistic scheme involves intramolecular single-electron transfer (SET) from the enamino 
moiety toward C-5 of the ring, and subsequent transannular interaction in zwitter-ionic biradical 
133a with formation of stabilized zwitter-ion 133b opening of the oxetane ring in leads to 
cyclobutene 134, while the secondary photolysis of latter gives the olefin 135 and alkyne 136 
(Scheme 62).54  
4.3.2 Synthesis of 2,4-disubstituted naptholpyrans. 
 Graham N. Wishart and his research group55 reported the synthetic utility of naphtho-
carbocyclic 2-aminopyrans under following conditions. The naphtho-carbocyclic 2-aminopyrans 
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of acetic acid as solvent medium to afford the 2-N-pyrrolo-carbonitriles 138. In the same way 
naphtho-carbocyclic 2-aminopyrans were reacted with N,N-carbonyldiimidazole and succinic acid 
in dimethylformamide solvent at 80-90 °C, to afford the 2-N-succinimido-carbonitriles 139 
(Scheme 63). They synthesized a series of 2,4-disubstituted naptholpyrans under the acidic 
conditions and found their biological activity for antiinflammatory activity. 
 
 
 
 
 
 
 
 
 
Scheme 63. Synthetic utility of naphthocarbonitrile 
4.3.3 Synthesis of tacrine-like analogs from 2-aminopyrans  
 In 1993 tacrine (9-amino-1,2,3,4-tetrahydroacridine, THA) was the first 
acetylcholinesterase inhibitor (AChEI) approved in the United States for the treatment of 
Alzheimers disease (AD). The tacrine and its analogs 142 were prepared using sloid-phase 
synthesis, using cyclohexanone 140 and anthranilonitriles 141 under the microwave irradiation 
(Scheme 64).  
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Scheme 64. General methodology for synthesis of tacrine 
 
Macro and his research group56 reported the synthesis of different tacrine derivatives from 
fuctionalized 2-amino-3-cyano-4H-pyrans 143 with cyclic ketones 144 undergoes Friedlander 
annulation in the presence of aluminum chloride catalyst under reflux conditions to afford the new 
acridine-type tacrines 145. The Friedlander annulation is a straight forward method for the 
synthesis of aza-heterocyclic compounds. And also, its well-appreciated tool for the generation of 
large libraries of related heterocyclic compounds which are related to pharmacological activities. 
 
 
 
 
Scheme 65. Synthetic utility of 2-aminopyrans for tacrine synthesis 
 
And they tested the prepared tacrine analogs showed the ability towards to inhibit the 
acetylcholinesterease (AChE) butyrylcholinesterease (BChE) and neuronal uptake of serotonin 
and noradrenaline. Changes in the size of the carbocyclic ring of tacrine produced modest potency 
against cholinesterase enzymes (Scheme 65). 
 
4.3.4 Synthetic utility of 2-aminopyrans for dihydrofurans and 2-sulfinylimine-chromenes  
 Dihydrofurans and chromenes and their hetero-fused compounds are important molecular 
structures in synthetic organic chemistry. Such as, fungicidal agents, potential antioxidants and 
pharmaceuticals compounds. Further, these compounds are extensively used in photo chromic 
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materials and also as precursors to flavylium dyes. Recently A. Krishnaiah and his research group57 
reported a one pot four component reaction for dihydrofurans via simple, efficient, catalyst free 
green protocol in water medium. First 2-amino-4H-pyrans 146 were synthesized using 
multicomponent reaction strategy, then 2-aminopyrans were treated with N-chlorosuccinimide in 
water medium to obtained hexahydrodihydrofuran-carboxamides 147. When 2-aminopyrans were 
treated with N-chlorosuccinimide in alcoholic medium furnishes the hexahydrodihydrofuran-
carboxylates 148.  
 In another methodology A. Krishnaiah and his research group reported the synthetic utility 
of 2-amino-4H-pyrans 146, using multi-component reaction strategy. Initially they were 
synthesized 2-aminocromenes using three components in one pot reaction of aldehyde, 1,3-
dicarbonylcompound and malononitrile to construct the 2-aminopyrans, in the next stage 2-
aminopyrans were reacted with N-chlorosuccinimide and aryl amine via sequential addition, to 
afford hexahydrobenzofuran-2-N-phenyl-corbaxamide 149 derivatives. In same way to 2-
aminopyrans N-chlorosuccinimide and thiophenol in sequential addition to afford the 2-N-
sulfinylimines 150 (Scheme 66). 
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Scheme 66. Synthetic utility of 2-aminochromenes for the construct of dihydrobenzofurans and 2-
sulfinyl chromenes 
 
4.4 Previous report on enantioselective synthesis of spiro-conjugated 2-aminopyrans 
 W. C. Yuan and his research group reported58 the enantioselective construction of spiro-
conjugated 2-aminopyrans (spiro-[4H-3,3'-oxindoles] through domino 
knoevenagel/Michael/cyclization sequence catalyzed by cupreine (CPN) organocatalyst. In this 
study, they synthesized a wide range of optically active spiro-conjugated 2-aminopyrans with good 
to excellent enantioselectivities (up to 97%) under mild reaction conditions (Scheme 67).   
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Scheme 67. Synthesis of optically active spiro-conjugated 2-aminopyrans 
 
 They reported the Michael addition reaction of unsaturated isatin nitriles 151 with 
linear1,3-diketones 152 using cupreines 153d-f and cinchona-based alkaloids 153a-b as 
organocatalysts. Among them, the catalyst 153d have showed the excellent catalytic activity to 
afford chiral spiro-conjugated-2-aminopyrans 154 in both excellent chemical yields and 
enantioslectivities. However, this method failure to construct the chiral spiro-conjugated-2-
aminopyrans using with cyclic 1,3-dicarbonyl compounds. 
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4.5 Author strategy 
 Author aimed to develop the new hybrid type sqauaramide fused amino alcohol (SFAA) 
organocatalysts for chiral spiro-conjugated 2-aminopyrans from readily available Michael 
acceptors and cyclic 1,3-dicarbonyl compounds using domino Michael addition cyclization 
reaction as strategy. However, the construction of one unique spirocyclic-oxindole, incorporating 
a 2-amino- 4H-pyran-3-carbonitrile ring at the C3 position of oxindole, is still limited in synthetic 
organic chemistry (Figure 21).  
 
 
 
 
Figure 21. The hybrid structure of chiral spiro-conjugated 2-aminopyrans 
4.5.1 Synthetic utility of chiral spiro-conjugated 2-aminopyrans 
 The most fascinating application of spiro-conjugated 2-aminopyrans 157 in organic 
synthesis is undoubtedly due to the highly substituted spiro system of the molecules. The reactions 
of the amino and nitrile functional groups of spiro-conjugated 2-aminopyrans, mostly by 
nucleophilic additions or spiro-annulation, transform them into a 2-oxindole derivatives. The 
oxindoles skeletons system can be easily derived into a wide range of biologically active 
compounds, such as rhynchophylline (calcium channel blocker), elacomine (hemiterpene spiro-
alkaloid) and spirotryprostatin A (anti-mitotic agent). And also, the bifunctional -NH2 and -CN of 
spiro conjugated-2-aminopyrans shows reactivity towards electrophilic chlorination and 
brominating reactions.  
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Scheme 68. Synthetic utility of chiral spiro-conjugated 2-aminopyrans 
 
chiral spiro-conjugated 2-aminopyrans, especially those which are spiro-fused to other cyclic 
frameworks have drawn tremendous interest for researchers in the area of synthetic organic 
chemistry and medicinal chemistry. In particular, rhynchophylline 158, is an alkaloid found in 
certain uncaria species (Rubiaceae), rhynchophylline is a non-competitive NMDA antagonist and 
calcium channel blocker. And also, the spiro-oxindole moiety’s easily access to the synthesis of 
elacomine 159 hemiterpene spiro-alkaloid and spirotryprostatin A 160 which is an indolic alkaloid 
from the 2,5-diketopiperazine class of natural products found in the Aspergillus fumigatus fungus 
(Scheme 68). 
 
4.5.2 Results and discussions 
 In continuation of author efforts towards expanding the scope of amino alcohols and their 
derivatives as organocatalysts, author focused on the synthesis of squaramide fused amino alcohols 
and their applications for enantioselective reactions. The SFAA organocatalysts possess the 
multiple hydrogen-bonding and stereoinduction sites within the same molecule, and evaluated 
their catalytic activity in the Michael addition cyclization reaction to synthesis chiral spiro-
conjugated 2-aminiopyrans using 3-methylenedicyano-indo-2-one and cyclic 1,3-dicarbonyl 
compounds.  Additionally, SFAA catalysts contains a cyclic tertiary amino group that can act as a 
Brønsted base, sterically bulky groups, and two amino and one hydroxyl group that can form 
hydrogen bonds with both 3-dicyano-2-indanones and cyclic 1,3-dicarbonyl compound. As shown 
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in the plausible transition state X (Scheme 69). Thus, 3-dicyano-2-indanones and cyclic 1,3-
dicarbonyl compound can be conformationally fixed by hydrogen-bonding interactions, that is, 
between the two amino groups of the squaramide and the two nitrile groups of the isatin, between 
the cyclic ammonium site of the squaramide and the oxygen atom of the 1,3-dicarbonyl enolate 
moiety, and between the cyclic ammonium site and the hydrogen atom of the hydroxyl group in 
the ammonium alcohol intermediate.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Scheme 69. Conceptualization of SFAA catalyzed enantioselective Michael addition cyclization 
reaction 
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Then, the Michael addition reaction may proceed stereo-selectively to afford the Michael adduct 
initially, which upon undergoes cyclization to produce the 2-iminopyrans subsequently the 2-
iminiopyrans tautomerized into spiro-conjugated 2-aminopyrans to affords in a high 
enantioselectivities. 
4.5.3 The enantioselective Michael addition cyclization reaction using catalysts 29a-e 
 First, author examined the catalytic ability of SFAA catalyst 29a having a pyrrolidine ring 
at side chain of the catalyst for Michael addition cyclization reaction of 3-dicyano-2-indanone 
161a with dimedone 162a in toluene at room temperature (entry 1, Table 8), afforded the spiro-
pyran 163a in trace amount. Next, catalyst 29b is examined in toluene solvent at room temperature 
for 1h, afforded the spiro-pyran 163a in good chemical yield (82%) with poor enantiomeric excess 
(9% ee) (entry 2). Furthermore, the reaction was conducted at room temperature and 0 °C using 
catalyst 29b and 29c respectively afforded the spiro-pyran 163a in good to excellent chemical 
yields (catalyst 29c: 90% yield with 7% ee, catalyst 29b: 87% yield with racemic: entries 3,4). 
Moreover, reaction screened in THF solvent at 0 °C for 5h, afforded spiro-pyran 163a in excellent 
chemical yield (90%) in racemic. Next reaction was examined with N-benzyl-3-dicyano-2-
indanone 161b with 162a using catalyst 29b in toluene solvent, afforded spiro-pyran 163b in 
excellent chemical yield (95%) but the optical yield was not found (entry 6). Next, reaction is 
examined in THF solvent, for 24 h, at 0 °C, afforded chiral spiro-pyran in both good chemical 
yield (89%) and enantioselectivities (79 % ee) (entry 7). Subsequently the Michael reaction were 
optimized with catalysts 29a and 29b in THF solvent at 0 °C respectively, afforded chiral spiro-
pyran 163b in excellent chemical yields (92% and 95%) and good enantioselectivities (79% ee, 
75% ee) (entries 8,9). Moreover, the reaction also screened with catalysts 29d and 29e having 
morpholine and thiomorpholine rings at side chain of the catalysts, which afforded the chiral spiro-
pyran in excellent chemical yields (96%, 97%) but the enantiomeric excess was poor (entries 
10,11). By observing these results, next author examined the optimization reaction conditions for 
Michael addition reaction of N-benzyl-3-dicyano-2-indanone 161b with dimedone 162a using 
catalyst 29a in THF solvent at 0 °C for 48h.  
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Table 8. The enantioselective Michael addition cyclization reaction using catalysts 29a-e 
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 yield [%]b  ee [%]c
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tolueneb 82 9
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1
1
4
5
toluene 5b 87 rac
THF 5b 90 rac
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0
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(1.0 mL). bIsolated yields. cEnantiomeric excess was determined on chiral HPLC using Chiralpak AD-H 
and Chiralcel OD-H columns.
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4.5.4 The optimization of reaction conditions for asymmetric Michael addition cyclization 
reaction using catalyst 29a 
 Next, author inspected various reaction temperatures, molar ratios and solvents for Michael 
addition reaction using catalyst 29a for 48h (entries 1-15, Table 9). Changing the molar ratio of 
the catalyst 29a to 20 and 5 mol% also provided the spiro-conjugated 2-aminopyran 163b in 
excellent chemical yield with abnormal differences in enantiomeric excess, 20 mol % of the 
catalyst loading afforded the spiro-pyran with poor enantiomeric excess (7% ee).  
Table 9. Optimization of reaction conditions using with catalyst 29a 
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While the 5 mol % catalyst loading afforded 163b with good enantiomeric excess 83% (entries 
1,2). Next, the reaction screened with 2 mol % of catalyst 29a afforded the spiro-pyran 163b in 
92% chemical yield with 81% enantiomeric excess (entry 3). Furthermore, Michael reaction was 
examined at lower temperature such as -10 °C, -50 °C and -80 °C afforded the spiro-pyran 163b 
in decreasing chemical yields from (92% to 87%) and slight variations in enantioselectivities. At 
-10 °C afforded the spiro-pyran in 73% ee, at -50 °C afforded the spiro-pyran in 81% ee while -80 
°C afforded the spiro-pyran with 77% ee (entries 4-6). Next, Michael reaction was optimized in 
ethereal solvent such as Et2O, DIPE (diisopropyl ether) and 1,4-dioxane using catalyst 29a 
afforded spiro-pyran 163b with excellent chemical yields (82-98%) and poor to moderate 
enantioselectivities (5-67% ee) (entries 7-9). Furthermore, Michael reaction was also screened in 
chlorinated solvents such as DCM, chloroform and DCE using catalyst 29a afforded the spiro-
pyran 163b in excellent chemical yields (89-96%) with poor to moderate enantioselectivities (7-
51% ee) (entries 10-12). Subsequently the reaction was also optimized in polar solvents such as 
DMF, DMA and MeOH afforded the spiro-pyran in excellent chemical yields (89-92%) but the 
spiro-pyran 163b was found in racemic (entries 13-15). Form above results, author optimized the 
reaction conditions (catalyst 5 mol %, at 0 °C, for 48h) for enantioselective domino Michael 
addition cyclization reaction.  
 
4.5.5 Substrate scope for the enantioselective domino Michael addition cyclization reaction 
 The generality of protocol for the enantioselective domino Michael addition cyclization 
reaction was fully demonstrated by evaluating the reactions with between N-substituted 3-
dicayano-2-indanones 161c-j and cyclic 1,3-dicarbonyl compounds 162a,b using optimized 
catalyst 29a in THF solvent at 0 °C for 48 h (Scheme 70). First, the author examined the N-(4-
methoxybenzyl)-3-dicyano-2-indanone 161c as Michael acceptor with dimedone 162a using 
catalyst 29a, afforded chiral spiro-pyran 163c in both good chemical yields and enantiomeric 
excess (89%, 81% ee). Next the reaction was optimized with N-Boc group containing 3-dicyano-
2-indanone 161d with 162a afforded the spiro-pyran 163d in good chemical yield with poor 
enantioselectivity (5% ee).  
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Scheme 70. Substrate scope for enantioselective domino Michael addition reaction 
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 Furthermore, Michael reaction was screened with N-methyl-3-dicyano-2-indanones 161a 
with 162a afforded chiral spiro-pyran 163e in both excellent chemical yields (92%) and 
enantiomeric excess (95%). The absolute configuration of chiral spiro-pyran (3S)-163e were 
determined using with X-ray crystallography. Next, The N-ethy-3-dicyano-2-indanone 161f 
screened with 162a using catalyst 29a afforded chiral spiro-pyran in both good chemical yield 
(87%) and enantiomeric excess (84%). Additionally, the Michael reaction was screened with N-
(monomethoxymethylether)-3-dicyano-2-indanone 161g and N-(acetyl)-3-dicyano-2-indanone 
143h with dimedone 162a using catalyst 29a respectively, which afforded the chiral spiro-pyrans 
in excellent chemical yields (90 to 95%) and good to moderate enantioselectivities (75-80% ee). 
Furthermore, the enantioselective Michael addition reaction was screened with sterically bulky 
protected 2-methylene naphthyl and silyl protected 3-dicyano-2-indanones 161i and 161j with 
162a which afforded the chiral spiro-pyrans 163i and 163j respectively in both good chemical 
yields (72-81%) and enantioselctivities (71-76% ee). While changing the 1,3-cyclopentadione 
162b as Michael donor in reaction with N-methyl-3-dicyano-2-indanone 161e using catalyst 29a 
afforded the spiro-pyran 163k in excellent chemical yield (90%) and with moderate enantiomeric 
excess (76% ee).  
 
4.5.6 Plausible reaction course for domino Michael addition cyclization reaction  
 Based on the observed enantiopurities of chiral spiro-pyran 163e in 95% ee which afforded 
in Michael addition reaction with 161e with 162a, a model of mechanistic pathway for domino 
Michael addition cyclization reaction is proposed as follows (Scheme 72). First, the active 
methylene proton of dimedone is abstracted by basic tertiary amino group on pyrrolidine ring of 
catalyst 29a to form enolate, which might also induce the strong hydrogen bonding interaction 
between the hydrogen atom of the ammonium moiety on pyrrolidine ring in catalyst and oxygen 
atom of enolate. Next, N-(methyl)-3-dicyano-2-indanone 161e might fixed with catalyst 29a 
through two hydrogen bonds between two nitriles functionalities of 161e with two primary amino 
groups on squaramide unit of catalyst 29a. In the two possible transition states TS-I and TS-II, 
the TS-II has less steric interaction than that of TS-I, which has strong steric repulsion between 
dimethyl groups from dimedone with amide carbonyl oxygen atom of 161e. Hence the 
enantioselective Michael addition cyclization reaction might proceed via TS-II, in which the 
dimedone enolate co-ordinated to ammonium moiety on pyrrolidine ring could attack 
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stereoselectively on the electron deficient olefin carbon of 161e from the above side (Si  face) 
which leading to the formation of (3S)-163e as major isomer, whereas the minor isomer (3R)-163e' 
might be obtained through the unfavoured transition state TS-I (Scheme 71). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 71. Plausible reaction course for enantioselective domino Michael addition cyclization 
reaction using catalyst 29a 
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4.6 Summary 
 In summary, author developed new hybrid type squaramide fused amino alcohol (SFAA) 
catalyst 29a showed the significant catalytic activity in enantioselective domino Michael addition 
cyclization reaction with various N-substituted-3-dicyano-2-indanones 161a-j and cyclic 1,3-
dicarbonyl compounds 162a,b. This protocol provides the chiral spiro-conjugated 2-aminopyrans 
163a-k in both excellent chemical yields (up to 98%) and enantioselectivities (up to 95% ee). The 
resulted chiral spiro-conjugated-2-aminopyrans could be crucial intermediates for the synthesis of 
many biologically active significant scaffolds. 
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5. Conclusion 
 Many biological active molecules, including pharmaceuticals, are optically active. In 
biological systems of human beings only one form of enantiomers plays key role in treatment of 
diseases. Therefore, synthesis of optically active molecules is often more challenging in the field 
of synthetic organic chemistry. The catalytic asymmetric synthesis is useful for the preparation of 
biologically active molecules including a drug. The enantioselective synthesis using 
organocatalysts is recognized as an independent synthetic tool besides asymmetric metal catalysis 
and enzyme catalysis, and the catalysts are easy to handle even on large scale and relatively less 
toxic compared to transition metals. In the present thesis, author aimed to develop an efficient new 
hybrid type squaramide fused amino alcohol (SFAA) organocatalysts for enantioselective 
reactions. The SFAA organocatalysts were prepared by using with simple amino alcohol with 
mono ester squaramide and the catalysts possess with multiple activation sites in the molecule such 
as, three hydrogen bonding sites from two amine functions and one hydroxy function. And also, 
contains an Brønsted basic site on the side chain of catalysts from cyclic amines (pyrrolidine, 
piperidine, azapane, morpholine and thiomorpholine) which can abstract the proton from pro-
nucleophiles. By these properties of SFAA organocatalysts enables the formation of covalent and 
non-covalent intermediates with wide-variety of the substrates and allows one enantiomeric face 
for enantioselective reactions. The prepared SFAA organocatalysts successfully applied for 
enantioselective nitro-aldol (chapter 2), Diels-Alder (chapter 3) and domino Michael addition 
cyclization reactions (chapter 4).  
 In chapter 2, author discussed about the detailed application of SFAA organocatalysts for 
enantioselective nitro-aldol reaction. The usual and new hybrid type SFAA organocatalysts 21a-d 
and 29a-e were prepared and examined in enantioselective nitro-aldol reaction of isatins 30a-k 
with nitromethane 7. Among the prepared SFAA organocatalysts, the catalysts 29c has showed 
the best catalytic activity to afford the chiral 3-alkylated-3-hydroxy-oxindoles 31a-k in excellent 
chemical yields and enantioselectivities (up to 99%, up to 95% ee). The obtained chiral 3-
alkylylated-3-hydroxy-oxindoles 31a-k are prominent synthetic intermediates for many 
biologically active compounds such as the donaxaridine (anticancer), spirobrasinin (antifungal), 
maremycin B (cytotoxicity) and CPC-1 (antibacterial agent).  
 In chapter 3, author discussed about the detailed application of SFAA organocatalysts for 
enantioselective Diels-Alder reaction. The new hybrid type SFAA organocatalysts 29a-e showed 
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catalytic activity for enantioselective Diels-Alder reactions of 3-hydroxy-2-pyridones 96a,b and 
4-substituted 3-hydroxy-2-pyridones 99a-d with maleimides 97a-k respectively. Among the 
optimized SFAA catalysts, the catalysts 29a showed best catalytic activity to afford the chiral 4-
hydroxyisoquinnuclidines 98a-k and 101a-f in excellent chemical yields and enantioselectivities 
(up to 95%, up to 98% ee) respectively. Particularly, the reaction of 4-brominated 2-pyridone 99a 
with maleimides 97a afforded the corresponding 4-hydroxyisoquinnuclidines 101a in both 
excellent chemical yield and enantioselectivity (up to 95%, up to 98% ee) having an opposite 
absolute stereochemistry in comparison with the DA adduct 98a from the reactions using common 
3-hydroxy-2-pyridone 96a. The obtained chiral 4-hydroxyisoquinnuclidines 98a-k and 101a-f are 
prominent synthetic intermediates for bicyclic complex structures and many biological active 
molecules such as oseltamivir (antiinfluenza drug), ibogaine (natural product) and vinblastine and 
vincristine (anticancer drug). 
 In chapter 4, author discussed about the detailed application of new hybrid type SFAA 
organocatalysts for enantioselective domino Michael addition cyclization reaction. The new 
hybrid type SFAA organocatalysts 29a-e has showed catalytic activity for domino Michael 
addition cyclization reaction of cyclic 1,3-dicarbonyl compound 162a,b with electron withdrawing 
2-indanones 161a-j. Among the optimized SFAA organocatalysts, catalyst 29a has showed the 
best catalytic activity to afford chiral spiro-conjugated 2-aminopyrans 163a-k in excellent 
chemical yields and enantioselectivities (up to 97%, up to 95% ee). The obtained chiral spiro-
conjugated 2-aminopyrans 163a-k are the prominent synthetic intermediates for many biologically 
active analogs, such as tacrine derived 2-aminopyrans (antialzheimers), spiro-pyranopyrazoles 
(antioxidants), pyranopyranones (anticoagulant) and 2-aminotetrahydrocromenes 
(antileishmaniasis). 
 In conclusion, author developed new hybrid type squaramide fused amino alcohol (SFAA) 
organocatalysts. The prepared SFAA organocatalysts successfully applied in enantioselective 
nitro-aldol, Diels-Alder and domino Michael addition cyclization reactions which afforded the 
biological active chiral synthetic intermediates in excellent chemical yields and 
enantioselectivities. It’s expected that these results might be able to contribute greatly in the 
development of new synthetic drugs in the field of synthetic organic chemistry. 
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6. Experimental section  
 General information: All commercial reagents were purchased and used without further 
purification. All reactions were carried out under argon in flame-dried glassware with magnetic 
stirring. Thin layer chromatography was performed on silica gel 60 F254, and the analytes were 
detected by using UV light (254 nm) and iodine vapor. Column chromatography was carried out 
on silica gel 60N (40-100 µm). Melting points were measured with a micro melting point 
apparatus. 1H NMR (500 MHz) and 13C NMR (125 MHz) spectroscopic data were recorded in 
either CDCl3 or (CD3)2SO. The 1H NMR spectral data are reported as follows: chemical shifts (δ) 
in ppm from tetramethylsilane (δ = 0.0 ppm) or the residual solvent as an internal standard [for 
CDCl3: δ = 7.26 ppm; for (CD3)2SO: δ = 2.50 ppm], multiplicity [s (singlet), d (doublet), t (triplet), 
q (quartet), dd (doublet of doublets), m (multiplet), and br. (broad)], coupling constants in Hertz 
(Hz), integration, and assignment. The 13C NMR spectroscopic data were measured with complete 
proton decoupling. Chemical shifts are reported in ppm from the residual solvent as an internal 
standard (for CDCl3: δ = 77.16 ppm). IR spectra were measured with an JASCO 4100 FT-IR 
spectrophotometer. 1H (500 MHz) and 13C NMR (125 MHz) spectroscopic data were recorded 
using JEOL JNM-ECA500 instrument. Optical rotations were measured with a JASCO DIP-360 
digital polarimeter. HRMS data were obtained by EI and FAB using Hitachi RMG-GMG and 
JEOL JNX-DX303 sector instruments. 
Chapter 2: The New Hybrid Type Squaramide Fused Amino Alcohol Organocatalysts For 
Enantioselective Nitro-Aldol Reaction of Nitromethane with Isatins 
General procedure for the synthesis of compounds (21a-d): To a stirred solution of compound 
squaramide mono ester amide 20 (149 mg, 1 mmol) in dry MeOH (5 mL) was added the 
corresponding amino alcohol 19a-d (1 mmol) at room temperature, and the resulting mixture was 
stirred at the same temperature for 12 h. Upon completion of the reaction indicated by TLC, the 
excess amount of MeOH was evaporated under reduced pressure to give the crude reaction 
mixture, which was purified by flash column chromatography (hexane/EtOAc, 6:4) to afford 21a-
d as pure compounds in moderate to good yields. 
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(S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-1,1-diphenylpropan-2-
yl)amino)cyclobut-3-ene-1,2-dione (21a): Pale yellow solid (MeOH). 170 mg, 70% yield. m.p. 
202-205 °C. [α]D24 = –38 (c = 0.5, MeOH ). IR (neat) = 3223, 2980, 1687, 1417, 1115, 825 cm-1. 
1H NMR (500 MHz, DMSO-d6): δ 10.40 (s, 1H), 8.03 (s, 2H), 
7.99 (d, J = 10.50 Hz, 1H), 7.62 (s, 1H), 7.51 (t, J = 7.00 Hz, 
3H), 7.40 (t, J = 7.50 Hz, 2H), 7.26-7.20 (m, 3H), 7.09 (t, J = 
7.50 Hz, 1H), 6.42 (s, 1H), 1.00 (d, J = 7.0 Hz, 3H), 0.83 (d, J 
= 7.00 Hz, 3H).  13C NMR (125 MHz, DMSO-d6): δ 184.6, 180.0, 170.1, 161.8, 146.2, 145.3, 
141.1, 128.3, 127.8, 126.8, 126.4, 125.7, 125.6, 124.2, 122.1, 117.9, 114.6, 81.1, 63.6, 28.7, 22.3, 
17.5. EI-MS m/z: 534 (M)+, 556.8 (M + Na)+. HRMS (EI) calcd for C27H20F6N2O3 m/z: 534.1378 
(M)+ found: 534.1390. 
 
 (S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-3-methyl-1,1-diphenylbutan-
2-yl)amino)cyclobut-3-ene-1,2-dione (21b): White solid (ether). 150 mg, 65% yield. m.p. 197-
198 °C. [α]D24 = –647 (c = 0.5, MeOH). IR (neat) = 3215, 2986, 1696, 1497,740 cm-1. 1H NMR 
(500 MHz, DMSO-d6): δ 8.28 (s, 1H), 8.21 (d, J = 11.00 Hz, 
1H), 8.04 (d, J = 10.50 Hz, 1H), 7.50-7.43 (m, 4H), 7.34-7.23 
(m, 4H), 7.20-7.11 (m, 1H), 5.76 (s, 1H), 5.68 (s, 1H), 5.12-
5.10 (m, 1H), 4.40 (s, 1H), 4.19 (s, 1H), 0.93 (d, J = 7.00 Hz, 
3H), 0.75 (t, J = 6.50 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ 189.8, 182.4, 177.3, 173.1, 
146.8, 130.2, 129.3, 128.8, 128.3, 128.1, 127.9, 127.5, 126.6, 126.0, 125.8, 125.6, 125.5, 125.0, 
80.5, 63.7, 28.5, 22.4, 17.7. EI-MS m/z: 562 (M)+. HRMS (EI) calcd for C29H24F6N2O3 m/z: 
562.1691 (M)+ found: 562.1705. 
 
 (S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-3-phenyl-1,1-diphenylbutan-
2-yl)amino)cyclobut-3-ene-1,2-dione (21c): White solid (ether). 150 mg, 62% yield. m.p. 197-
198 °C. [α]D24 = –47 (c = 0.5, MeOH). IR (neat) = 3215, 2986, 1696, 1497,740 cm-1. 1H NMR 
(500 MHz, DMSO-d6): δ 10.4 (s, 1H), 8.80-8.78 (d, J = 10 Hz, 
1H), 8.01 (s, 2H), 7.64-7.69 (m, 3H), 7.35-7.38 (m, 2H), 7.08-
7.25 (m, 11H), 6.75 (br, 1H), 6.22-6.24 (d, J = 10 Hz, 1H). 13C 
NMR (125 MHz, DMSO-d6): δ 184.64, 179.96, 168.35, 162.61, 
145.61, 144.15, 140.82, 139.01, 131.36, 131.09, 128.93, 128.08, 127.52, 126.76, 126.62, 126.22, 
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126.15, 124.16, 121.99, 118.04, 114.8, 80.44, 63.38. EI-MS m/z: 596 (M)+. HRMS (EI) calcd for 
C32H22F6N2O3 m/z: 596.1581 (M)+ found: 596.3181. 
 
 (S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-1,1,3-triphenylpropan-2-
yl)amino)cyclobut-3-ene-1,2-dione (21d): White solid (MeOH). 100 mg, 59% yield. m.p. 253-
255 °C. [α]D24 = –25 (c = 0.5, MeOH). IR (neat) = 3265, 2986, 1686, 1446, 855 cm-1. 1H NMR 
(500 MHz, DMSO-d6): δ 10.15 (s, 1H), 8.05 (d, J = 10.00 Hz, 
1H), 7.93 (s, 2H), 7.66 (d, J = 7.50 Hz, 2H), 7.60 (s, 1H), 7.54 
(d, J = 7.50 Hz, 2H), 7.46 (t, J = 7.50 Hz, 2H), 7.29 (t, J = 7.50 
Hz, 1H), 7.19 (t, J = 7.50 Hz, 4H), 7.15-7.05 (m, 4H), 6.62 (s, 
1H), 5.47-5.41 (m, 1H), 2.83 (d, J = 7.00 Hz, 2H). 13C NMR 
(125 MHz, DMSO-d6): δ 183.8, 179.6, 169.6, 160.9, 145.4, 145.1, 141.0, 137.9, 131.5, 131.2, 
129.3, 128.6, 128.2, 127.9, 127.0, 126.4, 125.5, 124.2, 122.0, 117.6, 79.7, 62.2, 36.8. EI-MS m/z: 
610 (M)+, 633 (M + Na)+. HRMS (EI) calcd for C33H24F6N2O3 m/z: 610.1691 (M)+ found: 
610.1697.  
General procedure for the synthesis of compound (26): To a stirred solution of compound 24 
(1.0 g, 4.1 mmol) in dry DCM (20 mL) was added triethylamine (1.03 g, 10.2 mmol) and stirred 
for 5 min followed by addition of (Boc)2O (1.39 g, 6.3 mmol) then stirring was continued for 3 h 
at room temperature. After completion of the reaction indicated by TLC, reaction mixture was 
quenched with ice cold water and extracted with DCM (3x50 ml), solvent was evaporated under 
reduced pressure. The crude reaction mass of compound 25 (1.6 g, 4.6 mmol) was dissolved in dry 
DCM (20 mL) was added triethylamine (1.17 g, 11.6 mmol) and methanesulfonyl chloride (0.63 
g, 5.5 mmol) at 0 °C and reaction was allowed to stir at room temperature for 5 h. Then reaction 
mixture was quenched with ice cold water and extracted with DCM (3x50 ml), solvent was 
removed under vacuum and the residue was purified by flash column chromatography 
(hexane/ethyl acetate 9:1) to afford the compound 26 in good yield. 
 
(S)-2-((tert-butoxycarbonyl)amino)-3-hydroxy-3,3-diphenylpropyl-methanesulfonate (26): 
White solid (Ether). 1.9 g, 85% yield. m.p. 152-154 oC. [α]D21 = –57.14 (c = 0.7, EtOH). IR (neat): 
3012, 2966, 2817, 1622, 1456, 1158, 1028 cm-1. 1H NMR (CDCl3, 500 MHz): d  7.51 – 7.44 (m, 
4H), 7.35 – 7.18 (m, 6H), 5.25 (d, J = 8.5 Hz, 1H), 4.92 – 4.85 (m, 1H), 4.38 – 4.27 (m, 2H), 3.94 
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(bs, 1H), 2.86 (s, 3H), 1.33 (s, 9H). 13C NMR (CDCl3, 125 MHz) d: 156.1, 
144.4, 143.8, 128.8, 128.4, 127.6, 127.3, 125.6, 125.2, 80.4, 80.0, 69.5, 
56.0, 37.3, 28.2. FAB-MS m/z: 422 (M+H)+. HRMS (FAB) calcd for 
C21H28NO6S m/z: 422.1637 (M+H)+: found: 422.1634. 
 
General procedure for the synthesis compounds (27a-c): The Compound 26 (1.0 mmol) was 
charged in 50 mL round bottomed flask and the corresponding cyclic amine (3 mmol) was added 
drop-wise at room temperature. After 5 min stirring the temperature was raised to 70° C and 
allowed to stirred for 12 h. After completion of the reaction, indicated by TLC, the crude reaction 
mixture was purified by flash column chromatography using (hexane/EtOAc, 7:3) to afford the 
compounds 27a-e in moderate yield.  
 
(S)-tert-butyl-(1-hydroxy-1,1-diphenyl-3-(pyrrolidin-1-yl)propan-2-yl)carbamate  (27a): 
White solid (Ether). 65% yield. m.p. 113-115 oC. [α]D21 = –53.1 (c = 0.32, EtOH). IR (neat): 3096, 
2918, 2817, 2834, 1725, 1565,1456, 1165, 1018 cm-1. 1H NMR (CDCl3, 500 MHz): d  7.54 – 7.52 
(m, 2H), 7.48 – 7.47 (m, 2H), 7.31 – 7.24 (m, 4H), 7.17 – 7.13 (m, 2H), 
5.23 (d, J = 5.0 Hz, 1H), 4.63 (d, J = 5.0 Hz, 1H), 2.81 – 2.74 (m, 2H), 2.70 
– 2.60 (m, 2H), 2.40 – 2.30 (m, 2H), 1.78 – 1.68 (m, 4H), 1.35 (s, 9H).  13C 
NMR (CDCl3, 125 MHz) d: 155.8, 146.8, 145.2, 128.4, 128.2, 126.68, 
126.65, 125.3, 125.1, 81.7, 79.4, 56.3, 55.7, 54.3, 28.4, 28.3, 23.7. EI-MS m/z: 396 (M)+. HRMS 
(EI) calcd for C24H32N2O3 m/z: 396.2413 (M)+: found: m/z: 396.2417 (M)+. 
 
(S)-tert-butyl(1-hydroxy-1,1-diphenyl-3-(piperidin-1-yl)propan-2-yl)carbamate (27b): White 
solid (Ether). 62% yield. m.p. 85-87 oC. [α]D21 = –88.0 (c = 0.25, EtOH). IR (neat): 3086, 2910, 
2856, 1721, 1623, 1555, 1467, 1148, 1022 cm-1. 1H NMR (CDCl3, 500 
MHz): d  7.59 – 7.51 (m, 2H), 7.50 – 7.44 (m, 2H), 7.30 – 7.20 (m, 4H), 
7.18 – 7.12 (m, 2H), 5.30 – 5.22 (m, 1H), 4.70 – 4.62 (, 1H), 2.76 – 2.73 
(m, 1H), 2.56 – 2.42 (m, 2H), 2.10 – 2.02 (m, 2H), 1.60 – 1.52 (m, 4H), 
1.42 – 1.30 (m, 12H). 13C NMR (CDCl3, 125 MHz) d: 155. 8, 147.5, 145.2, 128.4, 128.2, 126.7, 
126.6, 125.3, 125.2, 81.4, 79.4, 59.1, 56.3, 54.0, 28.4, 26.3, 23.7. EI-MS m/z: 410 (M)+. HRMS 
(EI) calcd for C25H34N2O3 m/z: 410.2569 (M)+: found: m/z: 410.2565 (M)+. 
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(S)-tert-butyl-(3-(azepan-1-yl)-1-hydroxy-1,1-diphenylpropan-2-yl)carbamate (27c): White 
solid (Ether). 55% yield. m.p. 67-69 oC. [α]D21 = –80.0 (c = 0.25, EtOH). IR (neat): 3094, 2895, 
2812, 1732, 1645, 1532, 1428, 1156, 1019 cm-1. 1H NMR (CDCl3, 500 
MHz): d  7.55 (d, J = 5.0 Hz, 2H), 7.48 (d, J = 10.0 Hz, 2H), 7.30 – 7.24 
(m, 4H), 7.18 – 7.12 (m, 2H), 5.28 – 5.20 (m, 1H), 4.68 – 4.62 (m, 1H), 
3.00 – 2.92 (m, 1H), 2.44 – 2.36 (m, 2H), 1.70 – 1.52 (m, 8H), 1.34 (s, 
9H). 13C NMR (CDCl3, 125 MHz) d: 155. 7, 146.9, 145.3, 128.4, 128.2, 126.7, 126.6, 125.3, 81.5, 
79.4, 59.0, 58.2, 54.0, 28.4, 27.9, 26.6. EI-MS m/z: 424 (M)+. HRMS (EI) calcd for C26H36N2O3 
m/z: 424.2726 (M)+: found: m/z: 424.2728 (M)+. 
 
General procedure for the synthesis of compounds (28a-e): The compounds 27a-e (1 mmol) 
were dissolved in DCM (10 mL) followed by slow addition of TFA (0.382 mL, 10 mmol) at 0 oC 
and stirred for 1 h at room temperature. After completion of reaction, indicated by TLC. The 
residue was basified using with saturated aq. NaHCO3 solution and extracted with DCM (3x15 
mL) and the combined organic layers were washed with brine and dried over Na2SO4.  The solvent 
was evaporated under reduced pressure to afford compounds 28a-e in good to excellent yield. 
 
(S)-2-amino-1,1-diphenyl-3-(pyrrolidin-1-yl)propan-1-ol (28a):  Light yellow solid (Ether). 
135 mg, 90% yield. m.p. 113-115 °C. [α]D24 = –74 (c = 1.09, EtOH ). IR (neat) = 2933, 2803, 1556, 
1448, 1355 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 8.50 Hz, 2H), 7.53 (d, J = 8.50 Hz, 
2H), 7.33-7.25 (m, 4H), 7.20-7.13 (m, 2H), 3.92 (q, J1 = 3.50, 7.00 Hz, 
1H), 2.76 (q, J1 = 7.00, 13.00 Hz, 1H), 2.62-2.60 (m, 2H), 2.42-2.40 (m, 
2H), 2.28 (dd, J1 = 3.50, 13.00 Hz, 1H), 1.76-1.70 (m, 4H). 13C NMR (125 
MHz, CDCl3): δ 146.3, 145.8, 128.4, 128.2. 126.6, 126.5, 125.9, 125.6, 
79.9, 57.6, 55.1, 55.0, 23.7; FAB-MS m/z: 297 (M+H)+. HRMS (FAB) calcd for C19H25N2O m/z: 
297.1967 (M+H)+ found: 297.1963. 
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(S)-2-amino-1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol (28b): Pale yellow solid (Ether). 145 
mg, 95% yield. m.p. 125-126 °C. [α]D25 = –66 (c = 1.38, EtOH). IR (neat) = 3432, 2836, 2321, 
1561, 1446 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 7.50 Hz, 2H), 7.51 (d, J = 7.50 Hz, 
2H), 7.33-7.24 (m, 4H), 7.20-7.15 (m, 2H), 3.96 (q, J1 = 4.50, 6.50 Hz, 
1H), 2.62-2.39 (m, 3H), 2.20-2.16 (m, 3H), 1.57-1.50 (m, 4H), 1.38 (s, 2H). 
13C NMR (125 MHz, CDCl3): δ 146.9, 145.2, 128.3, 128.2, 126.6, 126.5, 
126.1, 125.8, 79.5, 59.1, 56.3, 54.0, 28.5, 26.3. FAB-MS m/z: 310 (M+H)+. 
HRMS (FAB) calcd for C20H27N2O m/z: 311.2123 (M+H)+: found: 311.2126.  
  
(S)-2-amino-3-(azepan-1-yl)-1,1-diphenylpropan-1-ol (28c): Pale yellow solid (Ether). 131 mg, 
86% yield. m.p. 145-146 °C. [α]D23 = –40 (c = 2.4, EtOH). IR (neat) = 3504, 2933, 2326, 1615, 
1452 cm-1. 1H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 8.50 Hz, 2H), 7.51 (d, J = 8.50 Hz, 2H), 
7.33-7.24 (m, 4H), 7.21-7.155 (m, 2H), 3.92 (q, J1= 4.50, 7.50 Hz, 1H), 
3.71 (s, 3H), 2.69-2.65 (m, 2H), 2.57-2.52 (m, 3H), 2.48 (dd, J1 = 4.50, 
13.50 Hz, 1H), 1.63-1.56 (m, 5H). 13C NMR (125 MHz, CDCl3): δ 
146.3, 145.5, 128.4, 128.3, 127.3, 126.6, 126.1, 125.7, 79.8, 59.9, 56.8, 
54.5, 28.0, 27.1. FAB-MS m/z: 325 (M+H)+. HRMS (FAB) calcd for C21H29N2O m/z: 325.2280 
(M+H)+: found: 325.2279. 
 
(S)-2-amino-3-morpholino-1,1-diphenylpropan-1-ol (28d): Light yellow solid (Ether). 130 mg, 
85% yield. m.p. 110-113 °C. [α]D23 = –66 (c = 1.0, EtOH). IR (neat) = 3386, 3324, 2950, 1599, 
1449, 1259 cm-1. 1H NMR (500 MHz, CD3OD): δ 7.29 (d, J = 8.00 Hz, 2H), 7.18 (d, J = 8.00 Hz, 
2H), 6.98 (t, J = 8.00 Hz, 2H), 3.76 (dd, J1 = 3.00, 9.00 Hz, 1H), 2.20 (s, 
2H), 2.10 (q, J = 9.00, 13.00 Hz, 1H), 1.88 (s, 2H), 1.83 (dd, J = 3.00, 
12.50 Hz, 1H).  13C NMR (125 MHz, CD3OD) δ: 147.6, 146.8, 129.5, 
129.3, 127.9, 127.8, 127.2, 126.8, 80.7, 68.2, 61.2, 55.4, 54.6. FAB-MS 
m/z: 313 (M+H)+. HRMS (FAB) calcd for C19H25N2O2 m/z: 313.1916 (M+H)+: found: 313.1904.  
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(S)-2-amino-1,1-diphenyl-3-thiomorpholinopropan-1-ol (28e): White solid (Ether). 131 mg, 
85% yield. m.p. 94-96 °C. [α]D25 = –74 (c = 1.09, EtOH). IR(neat) = 3582, 2952, 2359, 1673, 1491 
cm-1. 1H NMR (500 MHz, CD3OD): δ 7.73 (s, 1H), 7.48 (d, J = 7.50 Hz, 2H), 7.39 (d, J = 7.50 Hz, 
2H), 7.20-7.12 (m, 2H), 3.93 (s, 1H), 2.64 (s, 2H), 2.48 (s, 2H), 2.35 (s, 
2H), 2.30-2.25 (m, 3H), 2.12 (d, J = 13.00 Hz, 1H). 13C NMR (125 
MHz, CD3OD): δ 147.4, 146.8, 129.5, 129.3, 127.9, 127.8, 127.2, 126.2, 
126.9, 80.7, 61.5, 57.2, 54.9, 28.9. EI-MS m/z: 328 (M)+. HRMS (EI) 
calcd for C19H24N2OS m/z: 328.1609 (M)+: found: 328.1608. 
 
General procedure for the synthesis of compounds (29a-e): The compound 20 (100 mg, 1 
mmol) and corresponding amino alcohol 28 (1 mmol) were charged in sealed tube in 20 mL MeOH 
solvent were added and the sealed tube was closed tightly without any air gap and the reaction 
mixture was stirred for 12 h at 120 °C. After completion of the reaction indicated by TLC, the 
excess solvent was evaporated under reduced pressure resulted the crude mass, which was purified 
directly by flash column chromatography using (CHCl3/MeOH 9:1) to afford the compounds 29a-
e in moderate to good yield.  
 
(S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-1,1-diphenyl-3-(pyrrolidin-1-
yl)propan-2-yl)amino)cyclobut-3-ene-1,2-dione (29a): Brown solid (Ether). 99 mg, 56% yield. 
m.p. 145-146 °C. [α]D25 = –45 (c = 1.0, CHCl3). IR (neat): 3566, 3250, 3198, 2965, 1680, 1596 
cm-1. 1H NMR (500 MHz, CD3OD): δ 8.02 (s, 2H), 7.63 (d, J = 8.50 Hz, 2H), 7.55 (t, J = 7.50 Hz, 
3H), 7.39 (t, J = 8.00 Hz, 2H), 7.26 (t, J = 7. 50 Hz, 1H), 7.21 
(t, J = 7.50 Hz, 2H), 7.11 (t, J = 7.50 Hz, 1H), 5.45 (d, J = 
6.50 Hz, 1H), 3.00 (d, J = 8.50 Hz, 1H), 2.77 (s, 2H), 2.60 (d, 
J = 13.00 Hz, 1H), 2.46 (s, 2H), 1.78 (s, 4H). 13C NMR (125 
MHz, CD3OD): δ 186.1, 182.0, 171.6, 164.0, 146.5, 146.3, 142.6, 129.7, 129.2, 128.4, 128.1, 127.0, 
126.8, 127.0, 126.8, 125.8, 123.7, 119.2, 116.4, 58.9, 56.0, 24.5. EI-MS m/z: 603 (M)+. HRMS 
(EI) calcd for C31H27F6N3O3 m/z: 603.1957 (M)+: found: 603.1948. 
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(S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-1,1-diphenyl-3-(piperidin-1-
yl)propan-2-yl)amino)cyclobut-3-ene-1,2-dione (29b): Brown solid (Ether). 100 mg, 54% yield. 
m.p. 125-126° C. [α]D25 = –23.0 (c = 1.0, EtOH). IR (neat): 3554, 3447, 1794, 1733, 1671, 1558 
cm-1. 1H NMR (500 MHz, CD3OD): δ 8.02, (s, 2H), 7.64 (d, 
J = 7.00 Hz, 2H), 7.56 (d, J = 9.00 Hz, 2H), 7.50 (s, 1H), 7.40 
(t, J = 8.00 Hz, 2H), 7.27 (t, J = 7.50 Hz, 2H), 7.11 (t, J = 
7.50 Hz, 1H), 5.53 (d, J = 7.50 Hz, 1H), 3.17-2.80 (m, 3H), 
2.58 (s, 2H), 1.73-1.44 (m, 4H), 1.31-1.25 (m, 2H), 0.88 (t, J 
= 11.00 Hz, 1H). 13C NMR (125 MHz, CD3OD): δ 186.1, 182.0, 171.6, 164.2, 145.8, 142.4, 129.9, 
129.3, 128.6, 128.3, 127.1, 126.8, 125.8, 123.6, 119.2, 116.7, 81.4, 60.9, 59.4, 56.1, 32.9, 26.0, 
23.9, 14.6. FAB-MS m/z: 618 (M+H)+. HRMS (FAB) calcd for C32H30F6N3O3 m/z: 618.2191 
(M+H)+: found: 618.2203. 
 
(S)-3-((3-(Azepan-1-yl)-1-hydroxy-1,1-diphenylpropan-2-yl)amino)-4-((3,5-
bis(trifluoromethyl)phenyl)amino)cyclobut-3-ene-1,2-dione (29c): Yellow solid (Ether). 117 
mg, 62% yield. m.p. 161-162° C. [α]D23 = –23.0 (c = 1.0, EtOH). IR (neat): 3522, 3493, 1793, 1648 
cm-1. 1H NMR (500 MHz, CDCl3): δ 7.93 (s, 1H), 7.64-7.52 (m, 4H), 7.46 (d, J = 6.00 Hz, 2H), 
7.36 (t, J = 7.50 Hz, 3H), 7.23 (t, J = 6.00 Hz, 2H), 7.17-
7.14 (m, 2H), 7.05 (t, J = 7.00 Hz, 1H), 5.44 (s, 1H), 3.12 
(d, J = 14.00 Hz, 1H), 2.94 (s, 1H), 2.60 (s, 2H), 2.41 (s, 
2H), 1.61-1.35 (m, 8H). 13C NMR (125 MHz, CDCl3): δ 
182.4, 181.7, 171.6, 162.4, 143.6, 143.0, 139.7, 129.2, 
128.8, 127.7, 127.6, 125.2, 124.9, 124.0, 121.9, 117.7, 116.5, 115.3, 80.3, 59.7, 59.3, 57.8, 54.0, 
27.1, 26.8, 23.6, 22.5. FAB-MS m/z: 632 (M+H)+. HRMS (FAB) calcd for C33H32F6N3O3 m/z: 
632.2342 (M+H)+: found: 632.2341. 
 
(S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-3-morpholino-1,1-
diphenylpropan-2-yl)amino)cyclobut-3-ene-1,2-dione (29d): White solid (Ether). 142 mg, 78% 
yield. m.p. 238-240 °C. [α]D25 = –8.00 (c = 1.10, EtOH). IR (neat): 3589, 3423, 1797, 1568, 1541 
cm-1. 1H NMR (500 MHz, CD3OD): δ 8.03 (s, 2H), 7.58 (t, J = 7.50 Hz, 4H), 7.53 (s, 1H), 7.37 (t, 
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J = 7.50 Hz, 2H), 7.26-7.21 (m, 3H), 7.11 (t, J = 7.00 Hz, 
2H), 5.48 (t, J = 4.50 Hz, 1H), 3.63-3.54 (m, 4H), 2.70 (q, 
J1 = 9.50 Hz, 13.50 Hz, 3H), 2.54 (d, J = 12.00 Hz, 1H), 
2.24 (s, 2H).  13C NMR (125 MHz, CD3OD): δ 186.3, 181.8, 
171.8, 163.4, 146.6, 146.4, 142.6, 129.7, 129.3, 128.4, 
128.0, 126.7, 125.8, 123.7, 119.2, 116.6, 80.8, 68.2, 61.4, 60.0, 55.5. FAB-MS m/z: 620 (M+H)+. 
HRMS (FAB) calcd for C31H28F6N3O4 m/z: 620.1984 (M+H)+: found: 620.1984. 
 
(S)-3-((3,5-Bis(trifluoromethyl)phenyl)amino)-4-((1-hydroxy-1,1-diphenyl-3-
thiomorpholinopropan-2-yl)amino)cyclobut-3-ene-1,2-dione (29e): White solid (Ether). 151 
mg, 81% yield. m.p. 234-236 °C. [α]D25 = –11.00 (c = 1.0, EtOH). IR (neat): 3522, 3462, 1800, 
1652, 1573 cm-1. 1H NMR (500 MHz, CD3OD): δ 8.03 (s, 2H), 7.58 (t, J = 7.50 Hz, 4H), 7.53 (s, 
1H), 7.37 (t, J = 7.50 Hz, 2H), 7.26-7.21 (m, 3H), 7.11 (t, 
J = 7.00 Hz, 1H), 5.46 (m, 1H), 2.91 (t, J = 7.50 Hz, 2H), 
2.69-2.49 (m, 8H). 13C NMR (125 MHz, CD3OD) δ: 186.2, 
181.8, 171.8, 163.4, 146.7, 146.4, 142.5, 129.7, 126.3, 
128.4, 128.0, 126.9, 126.6, 125.8, 123.6, 119.1, 116.6, 80.8, 
61.6, 60.3, 57.2, 29.0. FAB-MS m/z: 636 (M+H)+. HRMS (FAB) calcd for C31H28F6N3O3S m/z: 
636.1756 (M+H)+: found: 636.1760.  
 
General Procedure for the synthesis of compounds (31b-k): To the stirred solution of isatins 
30b-k (20 mg, 1.0 equiv.)  and catalyst 29c (0.1 equiv.) in THF (2 mL) was added nitromethane 7 
(5.0 equiv.) at 0 °C and stirring was continued for appropriate times at same temperature. After 
completion of reaction indicated by TLC, the excess solvent was removed under reduced pressure 
yields the crude mass, which was purified by flash column chromatography using (Hexane/EtOAC 
6:4) solvent system to afford the nitro-aldol products 31b-k. The enantiomeric were determined 
by chiral HPLC using ChiralPak AD-H and AS-H columns. 
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(S)-tert-butyl 3-hydroxy-3-(nitromethyl)-2-oxoindoline-1-carboxylate (31e): Yellow solid. 24 
mg, 98% yield. m.p. 134-136 °C. [α]D23 = +2.8 (c = 1.0, EtOH). IR (neat): 3995, 1732, 1616, 1540, 
1191, 720 cm-1. (1H NMR, 500 MHz, CDCl3): δ 10.19 (s, 1H), 7.77 (t, J = 8.00 Hz, 1H), 7.66 (t, J 
= 8.00 Hz, 1H), 7.44 (t, J = 9.00 Hz, 1H), 7.25-7.19 (m, 1H), 7.08 (s, 1H), 
5.22 (q, J1 = 14.00, 19.00 Hz, 2H), 1.58 (s, 9H). 13C NMR (125 MHz, 
CDCl3): δ 173.5, 148.9, 140.3, 131.2, 127.1, 125.3, 125.0, 115.3, 84.7, 78.5, 
72.6, 28.4. EI-MS m/z: 308 (M)+. HRMS (EI) calcd for C9H8N2O4 m/z: 
208.0484 (M-Boc)+: found: m/z: 208.0491 (M-Boc)+. The enantiomeric 
excess was determined by HPLC; DAICEL chiralpak AD-H column, (solvent system (hexane/2-
propanol) 85:15; flow rate 1.0 mL/min, detection UV 254 nm; retention time 10.27 min (major) 
and 17.46 min (minor), ee = 95 %). 
 
(S)-3-hydroxy-5-iodo-3-(nitromethyl)indolin-2-one (31k): Brown solid. 24 mg, 97% yield. m.p. 
160-161 °C. [α]D21 = +53.3 (c = 0.3, EtOH). IR (neat): 3991, 1730, 1615, 1543, 1182, 825 cm-1. 
1H NMR (500 MHz, DMSO-d6): δ 10.23 (s, 1H), 7.71 (d, J = 1.50 Hz, 1H), 7.57 (dd, J1 = 1.50, 
8.00 Hz, 1H), 6.79 (s, 1H), 6.66 (d, J = 8.0 Hz, 1H), 5.02 (q, J1 = 8.00, 
39.50 Hz, 2H). 13C NMR (125 MHz, DMSO-d6): δ 175.3, 142.4, 138.6, 
133.1, 130.7, 112.5, 84.6, 77.8, 72.4; EI-MS m/z: 333.9 (M)+. HRMS (EI) 
calcd for C9H7N2O4I m/z: 333.9450 (M)+: found: 333.9460. The 
enantiomeric excess was determined by HPLC; DAICEL chiralpak AD-H 
column, (solvent system (hexane/2-propanol) 85:15; flow rate 1.0 mL/min, detection UV 254 nm; 
retention time 12.51 min (minor) and 16.89 min (major), ee = 95 %). 
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Theoretical calculations 
 The gas phase geometry optimization of the molecules leading to energy minima was 
achieved using the B3LYP hybrid functional with the 6-31G(d) basis set as implemented in the 
Gaussian 09. For all optimized structures, vibrational normal mode analysis was carried out to 
ensure that the obtained structures were corresponding to minimum energy state.  
 
1) Gaussian 09, Revision D.01, 
M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. 
Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, 
R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. 
N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. 
S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. 
Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. 
Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, 
P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, 
J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2013. 
Table S1. Cartesian coordinates (Angstroms) for 7. 
Point Group: C1 
Total energy = -414.73904622 hartree 
Symbol X Y Z 
C -0.69483 0.630929 -0.01183 
C 0.694817 0.63089 -0.01182 
C 0.773873 -0.85541 -0.00734 
C -0.77383 -0.85544 -0.00725 
O -1.6942 -1.64271 0.01256 
O 1.694236 -1.64269 0.012404 
N -1.69573 1.541533 -0.04631 
H -2.62735 1.190591 0.136318 
H -1.5357 2.507005 0.201903 
N 1.695716 1.541776 -0.04665 
H 1.535579 2.506321 0.205273 
H 2.627053 1.19038 0.136876 
 
Table S2. Cartesian coordinates (Angstroms) for 30a. 
Point Group: C1 
Total energy = -513.06346656 hartree 
Symbol X Y Z 
C -2.64303 0.801652 -0.00028 
C -2.75694 -0.59401 0.000096 
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C -1.6325 -1.43064 0.0003 
C -0.3823 -0.82532 0.000254 
C -0.25463 0.5786 -0.00019 
C -1.37979 1.397911 -0.00049 
H -3.53775 1.416287 -0.00039 
H -3.74459 -1.04721 0.000185 
H -1.74092 -2.51126 0.000471 
H -1.25983 2.477471 -0.00073 
C 1.181637 0.899999 0.000078 
C 1.909511 -0.49268 -0.00011 
O 1.749486 1.969806 0.000743 
O 3.098802 -0.71151 -0.00062 
N 0.884436 -1.42729 0.000258 
H 1.053908 -2.42376 -0.00024 
 
Table S3. Cartesian coordinates (Angstroms) for 30a. 
Point Group: C1 
Total energy = -245.00932811 hartree 
Symbol X Y Z 
N 0.173845 -0.00011 -0.01168 
O 0.732444 1.092099 0.003192 
O 0.730299 -1.09321 0.003236 
C -1.32526 0.001028 -0.0026 
H -1.66502 0.91265 -0.49085 
H -1.66722 -0.90041 -0.50823 
H -1.63506 -0.00883 1.045001 
 
Table S4. Cartesian coordinates (Angstroms) for Complex A (7 + 30a). 
Point Group: C1 
Total energy = -927.82276495 hartree 
 
Symbol X Y Z 
C 3.281111 0.736693 -0.14973 
C 3.421373 -0.61779 0.149173 
C 4.901437 -0.52533 0.223862 
C 4.746214 0.974288 -0.11256 
O 5.443092 1.955326 -0.28077 
O 5.782951 -1.32968 0.45252 
N 2.261307 1.574223 -0.4292 
H 2.482575 2.560079 -0.46886 
H 1.30178 1.331783 -0.20956 
N 2.593896 -1.66162 0.358593 
H 1.621988 -1.63231 0.070832 
H 3.023265 -2.57459 0.424907 
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C -5.2444 1.514967 0.319302 
C -5.82171 0.255126 0.116042 
C -5.04618 -0.89267 -0.1033 
C -3.66829 -0.73806 -0.11205 
C -3.07351 0.523839 0.091305 
C -3.85585 1.656968 0.30738 
H -5.87991 2.378689 0.485546 
H -6.9037 0.158461 0.127378 
H -5.51285 -1.86042 -0.2595 
H -3.38106 2.621244 0.461951 
C -1.62244 0.348343 0.018904 
C -1.40837 -1.18484 -0.24323 
O -0.72195 1.157301 0.123021 
O -0.35625 -1.77896 -0.36347 
N -2.67528 -1.71608 -0.30787 
H -2.85069 -2.69971 -0.46435 
 
Table S5. Cartesian coordinates (Angstroms) for Complex B (7 + 30a). 
Point Group: C1 
Total energy = -659.76437807 hartree 
Symbol X Y Z 
C -1.27292 -0.69431 -0.04863 
C -1.26923 0.69548 0.030308 
C -2.75259 0.775621 0.056425 
C -2.75692 -0.76842 -0.03533 
O -3.55337 -1.68333 -0.07685 
O -3.54407 1.693665 0.119141 
N -0.33966 -1.66479 -0.15501 
H -0.65798 -2.61754 -0.03886 
H 0.62964 -1.47574 0.070069 
N -0.32937 1.662455 0.112317 
H 0.632234 1.468876 -0.14012 
H -0.647 2.61599 0.000338 
N 3.261333 -0.01106 -0.01538 
O 2.702388 1.007235 -0.41407 
O 2.698955 -1.03687 0.358079 
C 4.755328 0.017801 0.057795 
H 5.013172 0.471515 1.017662 
H 5.114319 -1.00791 0.006076 
H 5.116177 0.635958 -0.76241 
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Chapter 3: The New Hybrid Type Squaramide Fused Amino Alcohol Organocatalysts For 
Enantioselective Diels-Alder Reaction of 3-Hydroxy-2-Pyridones with Maleimides 
General procedure for the synthesis of compounds (98a-k) and (101a-f): To a 4-mL of sample 
vial containing catalyst 29a (6 mg, 10 mmol), 3-hydroxy-2-pyridones 96a,b and 99a-d (20 mg, 
0.07 mmol) and 1mL of DCM were added. The solution was allowed to stir at 0 °C for an hour, 
followed by maleimides 97a-k (14 mg, 0.08 mmol) were added. After stirring for 23 h at same 
temperature, the solvent was removed under reduced pressure. The residue was purified by flash 
column chromatography (Hexane/EtOAc: 90:10 to 60:40) to afford the DA adducts 98a-k and 
101a-f. The enantiomeric excess was determined by chiral HPLC using Chiralpak AS-H and 
Chiralcel OD-H columns. 
 
(4R)-7-hydroxy-2-phenyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-(epiminomethano)isoindole-
1,3,8-(2H)-trione (98a): White solid. 28 mg, 96 % yield. m.p. 241-242 °C. [α]D23 = –14 (c = 0.7, 
MeOH). IR (neat): cm-1 = 3449, 3065, 1781, 1712, 1449, 1351, 1240, 1159. 1H NMR (500 MHz, 
CDCl3, ppm): δ 7.89 (d, J = 8.00 Hz, 2H), 7.45 (t, J = 7.00 Hz, 2H), 7.40 (t, J 
= 7.50 Hz, 1H), 7.35 (d, J = 8.00 Hz, 2H), 7.16 (d, J = 8.00 Hz, 2H), 6. 48 (q, 
J = 6.00, 8.50 Hz, 1H), 6.39 (d, J = 7.50 Hz, 1H), 5.84-5.82 (m, 1H), 4.07 (s, 
1H), 3.76 (q, J = 4.00, 8.00 Hz, 1H), 3.16 (d, J = 8.50 Hz, 1H), 2.45 (s, 3H). 
13C NMR (125 MHz, CDCl3, ppm): 172.6, 172.1, 169.8, 146.4, 136.8, 134.6, 
131.13, 130.14, 129.4, 129.33, 129.32, 128.2, 126.7, 78.0, 52.4, 47.4, 44.1, 21.9. MS (FAB): m/z 
= 439 [M+H]+, HRMS (FAB): calcd. for C22H18N2O6S m/z 439.0987; found: 439.0966. The 
enantiomeric excess was determined by chiral HPLC using CHIRALPAK AS-H cloumn (solvent 
system: MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 21.66 min 
(major) and 33.31 min (minor), ee = 64%). 
 
 (4R)-7-hydroxy-2-methyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-(epiminomethano)isoindole-
1,3,8-(2H)-trione (98b): White solid. 27 mg, 96 % yield. m.p. 231-232 °C. 
[α]D24 = –15 (c = 0.4, MeOH). IR (neat): cm-1 = 3456, 3072, 1778, 1709, 
1458, 1360, 1238, 1154, 1112. 1H NMR (500 MHz, CDCl3, ppm): δ 7.85 (d, 
J = 8.50 Hz, 2H), 7.33 (d, J = 8.00 Hz, 2H), 6.35 (q, J = 5.50, 7.50 Hz, 1H), 
6.24 (d, J = 8.00 Hz, 1H), 5.74-5.72 (m, 1H), 4.04 (s, 1H), 3.59 (q, J = 4.50, 
8.00 Hz, 1H), 3.02 (d, J = 8.50 Hz, 1H), 2.93 (s, 3H), 2.42 (s, 3H). 13C NMR (125 MHz, CDCl3, 
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ppm): 173.9, 173.2, 169.9, 146.3, 136.3, 136.7, 134.5, 130.1, 129.1, 128.2, 77.8, 52.2, 47.5, 44.1, 
25.4, 21.9. MS (FAB): m/z = 377 [M+H]+, HRMS (FAB): calcd. for C17H16N2O6S m/z 377.0814; 
found: 377.0809. The enantiomeric excess was determined by chiral HPLC using CHIRALPAK 
AS-H column (solvent system: MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; 
retention time 18.99 min (major) and 22.18 min (minor), ee = 22%). 
 
(4R)-7-hydroxy-2-ethyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-(epiminomethano)isoindole-
1,3,8-(2H)-trione (98c): white solid. 26 mg, 90 % yield. m.p. 134.5 °C. [α]D24 = –18 (c = 0.5, 
MeOH). IR (neat) cm-1 = 3458, 3070, 1771, 1700, 1451, 1355, 1218, 1144, 1113. 1H NMR (500 
MHz, CDCl3, ppm): δ 7.87 (d, J = 8.50 Hz, 2H), 7.34 (d, J = 8.00 Hz, 2H), 6.36 
(q, J = 5.50, 8.00 Hz, 1H), 6.25 (dd, J = 4.50, 8.00 Hz, 1H), 3.50 (q, J = 7.00, 
14.50 Hz, 2H), 2.99 (d, J = 8.00 Hz, 1H), 2.44 (s, 3H), 1.08 (t, J = 7.00 Hz, 3H). 
13C NMR (125 MHz, CDCl3, ppm): 173.4, 172.9, 169.9, 146.3, 136.5, 134.5, 
130.1, 129.0, 128.2, 77.8, 52.3, 47.3, 43.9, 34.3, 21.9, 12.9. MS (FAB): m/z = 
391 [M+H]+, HRMS (FAB): calcd. for C18H18N2O6S m/z 391.0988; found: 391.0966. The 
enantiomeric excess was determined by chiral HPLC using CHIRALPAK AS-H column (solvent 
system: MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 21.19 min 
(major) and 33.5 min (minor), ee = 26%). 
 
(4R)-7-hydroxy-2-(p-tolyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-(epiminomethano)isoindole-
1,3,8-(2H)-trione (98d): White solid. 30 mg, 90 % yield. m.p. 236.1 °C. [α]D23 = –20 (c = 0.2, 
MeOH). IR (neat): cm-1 = 3485, 2360, 1740, 1696, 1514, 1404, 1369, 1155, 1099. 1H NMR (500 
MHz, CDCl3, ppm): δ 7.89 (d, J = 8.50 Hz, 2H), 7.35 (d, J = 8.50 Hz, 2H), 7.25 (t, J = 7.00 Hz, 
2H), 7.03 (d, J = 8.00 Hz, 2H), 6.46 (q, J = 6.00, 8.00 Hz, 1H), 6.38 (d, J 
= 7.00 Hz, 1H), 5.84-5.81 (m, 1H), 4.17 (s, 1H), 3.75 (q, J = 4.50, 8.50 
Hz, 1H), 3.18 (d, J = 8.00 Hz, 1H), 2.44 (s, 3H), 2.36 (s, 3H). 13C NMR 
(125 MHz, CDCl3, ppm): 172.8, 172.4, 169.8, 146.3, 139.4, 136.7, 134.5, 
130.1, 130.3, 129.3, 128.4, 128.2, 126.0, 78.0, 52.4, 47.3, 43.9, 21.9, 21.3. 
MS (FAB): m/z = 453 [M+H]+, HRMS (FAB): calcd. for C23H20N2O6S 
m/z 453.1102; found: 453.1132. The enantiomeric excess was determined by chiral HPLC using 
CHIRALPAK AS-H column (solvent system: MeOH; flow rate 0.2 mL/min; temp 25°C; detection 
UV 254 nm; retention time 22.2 min (major) and 41.9 min (minor), ee = 25%). 
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(4R)-7-hydroxy-2-(4-fluorophenyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98e): White solid. 30 mg, 89 % yield. m.p. 202-
205 °C. [α]D24 = –15 (c = 0.2, MeOH). IR (neat): cm-1 = 3675, 1705, 1653, 1511, 1374, 1224, 1156, 
1090. 1H NMR (500 MHz, CDCl3, ppm): δ 7.87 (d, J = 8.00 Hz, 2H), 7.34 (d, J = 8.50 Hz, 2H), 
7.16-7.09 (m, 4H), 6.45 (q, J = 6.00, 8.00 Hz, 1H), 6.37 (dd, J = 1.00, 8.00 
Hz, 1H), 5.82-5.80 (m, 1H), 4.27 (s, 1H), 3.80-3.77 (m, 1H), 3.23 (dd, J = 
1.00, 8.50 Hz, 1H), 2.43 (s, 3H).  13C NMR (125 MHz, CDCl3, ppm): 172.7, 
172.2, 169.8, 163.4, 161.5, 146.4, 136.7, 134.4, 130.1, 129.3, 128.2, 128.1, 
126.9, 116.5, 116.3, 78.0, 52.3, 47.3, 43.9, 21.9. MS (FAB): m/z = 457 
[M+H]+, HRMS (FAB): calcd. for C22H17FN2O6S m/z 457.0891; found: 
457.0868. The enantiomeric excess was determined by chiral HPLC using CHIRALPAK AS-H 
column (solvent system:  MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; 
retention time 20.44 min (major) and 27.61 min (minor), ee = 36%). 
 
(4R)-7-hydroxy-2-(4-chlorophenyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98f): White solid. 30 mg, 85 % yield.  m.p. 225.7 
°C. [α]D24 = –11 (c = 0.2, MeOH). IR (neat): cm-1 = 3853, 1781, 1730, 1703, 1643, 1617, 1565, 
1495, 1342, 1089. 1H NMR (500 MHz, CDCl3, ppm): δ 7.89 (d, J = 8.50 
Hz, 2H), 7.42 (d, J = 9.00 Hz, 2H), 7.36 (d, J = 8.00 Hz, 2H), 7.14 (d, J = 
8.50 Hz, 2H), 6.47 (q, J = 5.50, 8.00 Hz, 1H), 6.38 (q, J = 4.00, 8.00 Hz, 
1H), 3.18 (d, J = 8.50 Hz, 1H), 2.45 (s, 3H).13C NMR (125 MHz, CDCl3, 
ppm): 172.4, 171.8, 169.7, 146.4, 136.8, 135.5, 134.5, 130.1, 129.6, 129.4, 
128.2, 127.4, 78.0, 52.3, 47.4, 44.1, 21.9. MS (FAB): m/z = 473 [M+H]+, 
HRMS (FAB): calcd. for C22H17ClN2O6S m/z 473.0516; found: 473.0562. The enantiomeric 
excess was determined by chiral HPLC; CHIRALPAK AS-H column (solvent system: MeOH; 
flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 23.1 min (major) and 
34.71 min (minor), ee = 35%). 
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(4R)-7-hydroxy-2-(4-bromophenyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98g): White solid. 35 mg, 92 % yield. m.p. 217.5 
°C. [α]D24 = –23 (c = 0.3, MeOH). IR (neat): cm-1 = 3735, 3352, 1711, 1595, 1490, 1364, 1272, 
1165, 1087. 1H NMR (500 MHz, CDCl3, ppm): δ 7.89 (d, J = 8.50 Hz, 
2H), 7.58 (d, J = 8.50 Hz, 2H), 7.36 (d, J = 8.50 Hz, 2H), 7.08 (d, J = 8.0 
Hz, 2H), 6.47 (q, J = 6.00, 8.00 Hz, 1H), 6.38  (d, J = 7.50 Hz, 1H), 5.84-
5.81 (m, 1H), 4.04 (s, 1H), 3.75 (q, J = 4.0, 8.50 Hz, 1H), 3.14 (d, J = 8.50 
Hz, 1H), 2.45 (s, 3H).  13C NMR (125 MHz, CDCl3, ppm): 172.2, 171.7, 
169.8, 146.4, 136.8, 134.6, 132.6, 130.16, 130.13, 129.4, 128.2, 127.7, 
123.2, 78.0, 52.3, 47.4, 44.1, 21.9. MS (FAB): m/z = 517 [M]+, HRMS 
(FAB): calcd. for C22H17BrN2O6S m/z 517.0096; found: 517.0095. The enantiomeric excess was 
determined by chiral HPLC using CHIRALPAK AS-H column (solvent system: MeOH; flow rate 
0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 24.5 min (major) and 39.0 min 
(minor), ee = 49%). 
 
(4R)-7-hydroxy-2-(4-iodophenyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98h): White solid. 33 mg, 78 % yield. m.p. 202–
205 °C. [α]D24 = –19 (c = 0.1, MeOH). IR (neat): cm-1 = 3744, 3587, 2362, 1710, 1489, 1374, 1167, 
1088, 993. 1H NMR (500 MHz, CDCl3, ppm): δ 7.89-7.87 (m, 2H), 7.76 (d, 
J = 9.00 Hz, 1H), 7.46-7.38 (m, 1H), 7.34 (d, J = 7.50 Hz, 2H), 7.16 (d, J = 
7.50 Hz, 1H), 6.93 (d, J = 8.50 Hz, 1H), 6.49-6.44 (m, 1H), 6.38 (t, J = 7.50 
Hz, 1H), 5.84-5.81 (m, 1H), 4.20 (s, 1H), 3.78 (q, J = 4.00, 8.00 Hz, 1H), 
3.21 (d, J = 8.00 Hz, 1H), 2.44 (s, 3H).13C NMR (125 MHz, CDCl3, ppm): 
172.7, 172.3, 171.8, 169.7, 146.4, 138.5, 136.7, 130.7, 130.1, 129.4, 128.2, 
127.9, 126.2, 78.0, 52.4, 47.4, 44.0, 21.9. MS (FAB): m/z = 564 [M]+, HRMS (FAB): calcd. for 
C22H17IN2O6S m/z 564.9950; found: 564.9958. The enantiomeric excess was determined by chiral 
HPLC using CHIRALPAK AS-H column (solvent system: MeOH; flow rate 0.2 mL/min; temp 
25°C; detection UV 254 nm; retention time 26.64 min (major) and 46.87 min (minor), ee = 36%). 
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(4R)-7-hydroxy-2-phenyl-9-mesitylsulfonyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98i): White solid. 29 mg, 92 % yield. m.p. 234.1 
°C. [α]D24 = 57 (c = 0.4, CH2Cl2). IR (neat): cm-1 = 3213, 2970, 1787, 1517, 1456, 1345, 1125, 
1109, 1098. 1H NMR (500 MHz, CDCl3, ppm): δ 7.46-7.38 (m, 3H), 7.17 (d, J 
= 8.00 Hz, 2H), 6.97 (s, 2H), 6.54 (t, J = 8.00 Hz, 1H), 6.50 (d, J = 5.50 Hz, 
1H), 5.88 (t, J = 4.00 Hz, 1H), 4.10 (s, 1H), 3.90 (q, J = 4.50, 8.50 Hz, 1H), 
3.24 (d, J = 8.50 Hz, 1H), 2.59 (s, 6H), 2.30 (s, 3H). 13C NMR (125 MHz, 
CDCl3, ppm): 172.7, 172.2, 170.6, 144.8, 141.1, 137.3, 132.3, 131.6, 131.1, 
129.3, 129.2, 129.0, 126.3, 78.1, 51.5, 47.9, 44.6, 22.7, 21.2. MS (FAB): m/z = 467 [M+H]+, 
HRMS (FAB): calcd. for C24H22N2O6S m/z 467.1204; found: 467.1272. The enantiomeric excess 
was determined by chiral HPLC using CHIRALPAK AS-H column (solvent system: MeOH; flow 
rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 23.3 min (major) and 31.8 min 
(minor), ee = 22%). 
 
(4R)-7-hydroxy-2-(4-bromophenyl)-9-mesitylsulfonyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (98j): White solid. 35 mg, 95 % yield. m.p. 221.5 
°C. [α]D24 = 90 (c = 0.4, CH2Cl2). IR (neat): cm-1 = 3821, 3742, 3567, 1780, 1700, 1670, 1489, 
1373, 1188, 1079. 1H NMR (500 MHz, CDCl3, ppm): δ 7.57 (d, J = 8.50 
Hz, 2H), 7.09 (d, J = 8.50 Hz, 2H), 6.98 (s, 2H), 6.55 (q, J = 5.50, 8.00 
Hz, 1H), 6.49 (d, J = 8.00 Hz, 1H), 5.89-5.87 (m, 1H), 4.11 (s, 1H), 3.91 
(q, J = 4.50, 8.50 Hz, 1H), 3.27 (d, J = 8.50 Hz, 1H), 2.59 (s, 6H), 2,30 (s, 
3H).13C NMR (125 MHz, CDCl3, ppm): 172.3, 171.9, 170.5, 144.9, 141.1, 
137.4, 134.4, 132.5, 132.4, 131.5, 130.1, 129.0, 127.7, 127.5, 123.1, 78.1, 
51.4, 47.9, 44.7, 22.7, 21.2. MS (FAB): m/z = 545 [M+H]+, HRMS (FAB): calcd. for 
C24H21BrN2O6S m/z 545.0401; found: 545.0404. The enantiomeric excess was determined by 
chiral HPLC using CHIRALPAK AS-H column (solvent system: MeOH; flow rate 0.2 mL/min; 
temp 25°C; detection UV 254 nm; retention time 29.83 min (major) and 38.17 min (minor), ee = 
38%). 
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(4S)-6-bromo-7-hydroxy-2-phenyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101a): White solid. 28 mg, 95 % yield. m.p. 
242.5 °C. [α]D25 = 40 (c = 0.1, MeOH). IR (neat): cm-1 = 3815, 3734, 1716, 1596, 1495, 1394, 
1342, 1291, 1205, 1153, 1086. 1H NMR (500 MHz, CDCl3, ppm): δ 7.91 
(d, J = 8.00 Hz, 2H), 7.47-7.40 (m, 3H), 7.37 (d, J = 8.50 Hz, 2H), 7.16 (d, 
J = 7.00 Hz, 2H), 6.72 (d, J = 6. 00 Hz, 1H), 5.83 (q, J = 4.50, 7.00 Hz, 1H), 
4.30 (s, 1H), 3.79-3.75 (m, 1H), 3.30 (d, J = 8.00 Hz, 1H), 2.46 (s, 3H). 13C 
NMR (125 MHz, CDCl3, ppm): 172.2, 171.1, 167.6, 146.6, 134.3, 130.9, 
130.2, 129.5, 129.4, 129.0, 128.8, 128.3, 126.4, 78.5, 53.3, 47.9, 44.0, 21.9. MS MS (FAB): m/z = 
517 [M]+, HRMS (FAB): calcd. for C22H17BrN2O6S m/z 517.0061; found: 517.0065. The 
enantiomeric excess was determined by chiral HPLC using CHIRALPAK AS-H column (solvent 
system: MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 21.2 min 
(major) and 24.8 min (minor), ee = 98%). 
 
(4S)-6-bromo-7-hydroxy-2-(4-bromophenyl)-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101b): White solid. 30 mg, 89 % yield. m.p. 245 
°C. [α]D23 = 32 (c = 0.2, MeOH). IR (neat): cm-1 = 3769, 2355, 1712, 1595, 1490, 1364, 1272, 
1165, 1087. 1H NMR (500 MHz, CDCl3, ppm): δ 7.89 (d, J = 8.50 Hz, 2H), 7.57 (d, J = 9.00 Hz, 
2H), 7.36 (d, J = 8.50 Hz, 2H), 7.04 (d, J = 9.00 Hz, 1H), 6.71 (d, J = 
6.50 Hz, 1H), 5.82 (q, J = 4.50, 7. 00 Hz, 1H), 4.37 (s, 1H), 3.82 (q, J 
= 4.50, 8.00 Hz, 1H), 3.35 (d, J = 7.50 Hz, 1H), 2.45 (s, 3H). 13C NMR 
(125 MHz, CDCl3, ppm): 172.0, 170.9, 167.6, 146.7, 134.2, 132.7, 
130.2, 129.9, 129.0, 128.8, 128.3, 127.9, 123.3, 78,5, 53.2, 47.9, 44.1, 
21.9. MS (FAB): m/z = 596 [M]+, HRMS (FAB): calcd. for 
C22H16BrN2O6S m/z 596.9130; found: 596.9131. The enantiomeric excess was determined by 
chiral HPLC using CHIRALPAK AS-H column (solvent system: MeOH; flow rate 0.2 mL/min; 
temp 25°C; detection UV 254 nm; retention time 23.55 min (major) and 29.03 min (minor), ee = 
74%). 
 
Ph
OH
Ts
O
O
O
N
N
Br
101a
N
N
O
O
O
Ts
HOBr
Br101b
 117 
(4S)-6-bromo-7-hydroxy-2-methyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101c): White solid. 23 mg, 90 % yield. m.p. 248 
°C. [α]D24 = 40 (c = 0.5, MeOH). IR (neat): cm-1 = 3723, 2880, 1767, 1627, 1347, 1222, 1095, 
1089. 1H NMR (500 MHz, CDCl3, ppm): δ 7.86 (d, J = 8.50 Hz, 2H), 
7.34 (d, J = 8.00 Hz, 2H), 6.60 (d, J = 6.50 Hz, 1H), 5.73 (q, J = 4.50, 
6.50 Hz, 1H), 4.25 (s, 1H), 3.60 (q, J = 4.00, 8.00 Hz, 1H), 3.19 (d, J = 
8.00 Hz, 1H), 2.95 (s, 3H), 2.43 (s, 3H). 13C NMR (125 MHz, CDCl3, 
ppm): 173.1, 172.1, 167.7, 146.6, 134.2, 130.2, 128.9, 128.6, 128.2, 78.3, 
53.1, 47.8, 44.2, 25.5, 21.9. MS (FAB): m/z = 456 [M+H]+, HRMS (FAB): calcd. for 
C17H15BrN2O6S m/z 456.9817; found: 456.9893. The enantiomeric excess was determined by 
chiral HPLC using CHIRALPAK AS-H column (solvent system: IPA:Hexane = 90:10; flow rate 
0.5 mL/min; temp 25°C; detection UV 254 nm; retention time 28.0 min (major) and 37.6 min 
(minor), ee = 62%). 
 
(4S)-6-bromo-7-hydroxy-2-phenyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101d): White solid. 26 mg, 92 % yield. m.p. 245 
°C. [α]D24 = 32 (c = 0.4, MeOH). IR (neat): cm-1 = 3931, 3869, 3488, 1603, 
1505, 1457, 1339, 1281, 1102, 976. 1H NMR (500 MHz, CDCl3, ppm): δ 
7.56 (d, J = 8.50 Hz, 2H), 7.08 (d, J = 8.50 Hz, 2H), 6.97 (s, 2H), 6.54 (q, J 
= 6.00, 8.00 Hz, 1H), 6.49 (d, J = 6.50 Hz, 1H), 5.89-5.86 (m, 1H), 4.10 (s, 
1H), 3.91 (q, J = 4.00, 8.50 Hz, 1H), 3.26 (d, J = 8.50 Hz, 1H), 2.58 (s, 6H), 
2.30 (s, 3H). 13C NMR (125 MHz, CDCl3, ppm): 172.3, 171.9, 170.5, 144.9, 141.1, 137.4, 134.4, 
132.5, 132.3, 131.5, 130.1, 129.0, 127.7, 127.4, 123.1, 78.1, 51.4, 47.9, 44.7, 22.7, 21.2. MS 
(FAB): m/z = 545 [M]+, HRMS (FAB): calcd. for C24H21BrN2O6S m/z 545.0345; found: 545.0357. 
The enantiomeric excess was determined by chiral HPLC; CHIRALPAK AS-H column (solvent 
system MeOH; flow rate 0.2 mL/min; temp 25°C; detection UV 254 nm; retention time 23.55 min 
(major) and 29.03 min (minor), ee = 74%).  
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(4S)-6-allyl-7-hydroxy-2-phenyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101e): White solid. 29 mg, 93 % yield. m.p. 224 
°C. [α]D24 = 23 (c = 0.4, MeOH). IR (neat): cm-1 = 3976, 3748, 1708, 1596, 1497, 1353, 1296, 
1226, 1188, 1084. 1H NMR (500 MHz, CDCl3, ppm): δ 7.89 (d, J = 8.00 
Hz, 2H), 7.46-7.38 (m, 3H), 7.35 (d, J = 8.00 Hz, 2H), 7.11 (d, J = 7.50 
Hz, 2H), 6.10-6.08 (m, 1H), 5.76 (q, J = 4.00, 6.00 Hz, 1H), 5.63-5.54 
(m, 1H), 5.02 (dd, J = 9.00, 10.00 Hz, 1H), 4.88 (dd, J = 15.50, 17.00 
Hz, 1H), 4.00 (s, 1H), 3.68 (q, J = 4.00, 8.00 Hz, 1H), 3.13 (d, J = 8.50 
Hz, 1H), 2.95-2.81 (m, 2H), 2.46 (s, 3H).13C NMR (125 MHz, CDCl3, ppm): 172.7, 172.1, 170.1, 
148.1, 146.3, 134.6, 132.5, 131.1, 130.1, 129.4, 129.3, 128.2, 126.3, 121.9, 118.7, 79.0, 52.2, 47.5, 
44.2, 33.5, 21.9. MS (FAB): m/z = 479 [M+H]+, HRMS (FAB): calcd. for C25H22N2O6S m/z 
479.1270; found: 479.1272. The enantiomeric excess was determined by chiral HPLC using 
CHIRALCEL OD-H column (solvent system: IPA/Hexane = 50/50; flow rate 0.5 mL/min; temp 
25°C; detection UV 254 nm; retention time 24.8 min (major) and 50.3 min (minor), ee = 75%). 
 
(4S)-6-propyl-7-hydroxy-2-phenyl-9-tosyl-3a,4,7,7a-tetrahydro-1H-4,7-
(epiminomethano)isoindole-1,3,8-(2H)-trione (101f): White solid. 28 mg, 90 % yield. m.p. 
225.5 °C. [α]D23 = 18 (c = 0.5, CH2Cl2). IR (neat): cm-1 = 3987, 3878, 3427, 2979, 1709, 1567, 
1478, 1345, 1234, 1125, 1089.  1H NMR (500 MHz, CDCl3, ppm): δ 
7.91(d, J = 8.50 Hz, 2H), 7.45 (t, J = 7.00 Hz, 2H), 7.40 (t, J = 7.50 Hz, 
1H), 7.35 (d, J = 8.00 Hz, 2H), 7.11 (d, J = 7.0 Hz, 1H), 6.09-6.07 (m, 
1H), 5.76 (q, J = 4.50, 6.00 Hz, 1H), 3.99 (s, 1H), 3.70 (q, J = 4.00, 6.00 
Hz, 1H), 3.12 (d, J = 8.50 Hz, 1H), 2.44 (s, 3H), 2.23-2.17 (m, 1H), 
2.08-2.01 (m, 1H), 1.36-1.211 (m, 2H), 0.74 (t, J = 7.50 Hz, 3H). 13C NMR (125 MHz, CDCl3, 
ppm): 172.8, 172.3, 170.3, 149.5, 146.2, 134.7, 131.2, 130.0, 129.4, 129.2, 128.2, 126.1, 120.9, 
79.2, 52.2, 47.6, 44.2, 31.2, 21.8, 20.1, 13.5. MS (FAB): m/z = 481 [M+H]+, HRMS (FAB): calcd. 
for C25H24N2O6S m/z 481.1421; found: 481.1431. The enantiomeric excess was determined by 
chiral HPLC using CHIRALPAK OD-H column (solvent system: IPA/Hexane: 50/50; flow rate 
0.5 mL/min; temp 25°C; detection UV 254 nm; retention time 58.0 min (major) and 51.6 min 
(minor), ee = 51%). 
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X-ray Crystallography of (101a): 
 Single crystals suitable for X-ray crystallography were obtained by a diffusion of 2-
propanol into a dichloromethane solution of 101a. X-ray diffraction data were collected at 150 K 
on a Rigaku XtaLAB mini diffractometer with graphite monochromated Mo Kα radiation (λ = 
0.71070 Å). The structure was solved by direct methods (SHELX 2013)[1] and expanded using 
Fourier techniques. The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were 
refined using the riding model. The final cycle of full-matrix least-squares refinement [2] on F2 was 
based on 4752 observed reflections and 289 variable parameters and converged (largest parameter 
shift was 0.00 times its esd.) with unweighted and weighted agreement factors of:  
 
R1 = S ||Fo| - |Fc|| / S |Fo| = 0.0478  
wR2 = [ S (w (Fo2 - Fc2)2 ) / S w(Fo2)2]1/2 = 0.1218  
 
 The goodness of fit[3] was 1.06. Unit weights were used. The maximum and minimum 
peaks on the final difference Fourier map corresponded to 0.22 and -0.64 e-/Å3, respectively. A 
total of 16453 reflections were measured and 4752 were unique (Rint = 0.0480). Crystal data and 
refinement statistics are shown in Table S1. Atomic coordinates Biso involving hydrogen atoms 
are listed in Table S2. Crystallographic data of 101a has been deposited with Cambridge 
Crystallographic Data Center, deposition no. CCDC 1552298. 
 
[1] Sheldrick, G.M. Acta Cryst., 2008, A64, 112-122. 
[2] Least Squares function minimized: (SHELXL2013) 
Sw(Fo2-Fc2)2     where w = Least Squares weights. 
[3] Goodness of fit is defined as:  
    [Sw(Fo2 - Fc2)2/(No - Nv)]1/2 
  where: No = number of observations 
        Nv = number of variables 
 
Table S1. Crystal data and structure refinement for (101a): 
 
A. Crystal Data  
 
 
Empirical Formula C22H17BrN2O6S 
Formula Weight 517.35 
Crystal Color, Habit colorless, block 
Crystal Dimensions 0.400 X 0.400 X 0.350 mm 
Crystal System orthorhombic 
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Lattice Type Primitive 
Lattice Parameters a =   8.6469(14) Å 
 b =  10.2464(16) Å 
 c =  23.712(4) Å 
 V = 2100.9(6) Å3 
 
 
  
Space Group Pca21 (#29) 
Z value 4 
Dcalc 1.636 g/cm3 
F000 1048.00 
µ(MoKa) 21.056 cm-1 
 
B. Intensity Measurements 
 
Diffractometer XtaLAB mini 
Radiation MoKa (l = 0.71075 Å) 
 graphite monochromated 
Voltage, Current 50kV, 12mA 
Temperature -123.0oC 
Detector Aperture 75.0 mm (diameter) 
Data Images 540 exposures 
w oscillation Range (c=54.0, f=0.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00o 
w oscillation Range (c=54.0, f=120.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00o 
w oscillation Range (c=54.0, f=240.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00o 
w oscillation Range (c=54.0, f=0.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00 
w oscillation Range (c=54.0, f=120.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00o 
w oscillation Range (c=54.0, f=240.0) -60.0 - 120.0o 
Exposure Rate  32.0 sec./o 
Detector Swing Angle 30.00o 
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Detector Position 50.00 mm 
Pixel Size 0.073 mm 
2qmax 55.0oNo. of Reflections Measured Total: 
16453 
 Unique: 4752 (Rint = 0.0480) 
 Parsons quotients (Flack x parameter): 1976 
 
Corrections Lorentz-polarization 
  Absorption 
  (trans. factors: 0.334 - 0.479) 
 
C. Structure Solution and Refinement 
 
Structure Solution Charge Flipping (Superflip) 
Refinement Full-matrix least-squares on F2 
Function Minimized S w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ s2(Fo2) + (0.0315 . P)2  
  + 0.0000 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2qmax cutoff 55.0o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 4752 
No. Variables 289 
Reflection/Parameter Ratio 16.44 
Residuals: R1 (I>2.00s(I)) 0.0344 
Residuals: R (All reflections) 0.0375 
Residuals: wR2 (All reflections) 0.0779 
Goodness of Fit Indicator 1.063 
Flack parameter (Parsons' quotients = 1976) 0.015(5) 
Max Shift/Error in Final Cycle 0.001 
Maximum peak in Final Diff. Map 0.22 e-/Å3 
Minimum peak in Final Diff. Map -0.64 e-/Å3 
 
 
Table S2-1. Atomic coordinates and Biso/Beq 
 
atom    x    y    z  Beq 
Br1     0.94209(4)  0.28893(4)  0.96282(2)  3.349(12) 
S2      0.29923(12)  0.30199(8)  1.07492(3)  1.637(16) 
O3      0.2253(3)  0.4116(2)  1.04920(10)  2.23(5) 
O4      0.7312(3)  0.0150(2)  0.88084(10)  2.30(5) 
O5      0.7736(3)  0.0524(2)  1.01117(9)  1.67(4) 
O6      0.2187(3)  0.1807(3)  1.07844(11)  2.24(5) 
O7      0.5685(3)  0.1199(3)  1.09159(9)  2.18(5) 
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O8      0.3225(3)  0.2892(2)  0.85400(10)  1.85(5) 
N9      0.4596(3)  0.2798(3)  1.03545(11)  1.48(5) 
N33     0.5338(3)  0.1502(3)  0.85392(11)  1.28(5) 
C11     0.3700(4)  0.3443(3)  1.14157(14)  1.46(5) 
C12     0.7288(4)  0.2713(3)  0.97342(13)  1.35(6) 
C13     0.6192(4)  0.0786(3)  0.89295(12)  1.40(6) 
C14     0.6253(4)  0.3624(3)  0.96085(14)  1.47(5) 
C15     0.5611(4)  0.1786(4)  1.04755(14)  1.46(6) 
C16     0.5610(4)  0.1439(3)  0.79415(13)  1.36(5) 
C17     0.6623(4)  0.1447(3)  0.99622(13)  1.22(5) 
C18     0.4182(4)  0.1970(3)  0.94146(13)  1.23(5) 
C19     0.5455(3)  0.0951(3)  0.95042(13)  1.16(5) 
C20     0.4615(4)  0.3211(3)  0.97519(12)  1.39(5) 
C21     0.4133(4)  0.2209(3)  0.87872(14)  1.28(5) 
C22     0.3419(4)  0.2588(4)  1.18597(15)  1.88(6) 
C23     0.4425(4)  0.4628(4)  1.14940(16)  2.19(7) 
C24     0.4633(4)  0.0696(4)  0.76135(15)  1.81(6) 
C25     0.4561(4)  0.4155(4)  1.24935(15)  2.11(7) 
C26     0.3852(5)  0.2961(3)  1.23979(14)  2.05(7) 
C27     0.6103(5)  0.1289(4)  0.67940(14)  2.16(7) 
C28     0.6833(5)  0.2117(4)  0.77045(14)  1.97(7) 
C29     0.4988(5)  0.4565(5)  1.30860(18)  3.02(8) 
C30     0.7078(4)  0.2032(4)  0.71280(17)  2.40(8) 
C31     0.4896(4)  0.0611(4)  0.70363(15)  2.27(7) 
C32     0.4876(5)  0.4961(4)  1.20411(16)  2.42(7) 
 
Beq = 8/3 p2(U11(aa*)2 + U22(bb*)2 + U33(cc*)2 + 2U12(aa*bb*)cos g + 2U13(aa*cc*)cos b 
+ 2U23(bb*cc*)cos a)
 
 
Table S2-2. Atomic coordinates and Biso involving hydrogen atoms 
 
atom    x    y    z  Biso 
H5A     0.73884  0.00475  1.03706  2.009 
H14     0.65089  0.44439  0.94464  1.761 
H18     0.31649  0.16205  0.95474  1.470 
H19     0.49858  0.01061  0.96280  1.390 
H20     0.38624  0.39336  0.96812  1.664 
H22     0.29417  0.17671  1.17950  2.256 
H23     0.46114  0.52000  1.11859  2.625 
H24     0.37883  0.02453  0.77801  2.172 
H26     0.36610  0.23918  1.27062  2.455 
H27     0.62662  0.12463  0.63982  2.591 
H28     0.74954  0.26326  0.79338  2.366 
H29A    0.59985  0.49973  1.30817  3.630 
H29B    0.50360  0.37925  1.33292  3.630 
 123 
H29C    0.42052  0.51696  1.32311  3.630 
H30     0.79187  0.24868  0.69611  2.876 
H31     0.42420  0.00857  0.68082  2.730 
H32     0.54103  0.57577  1.21031  2.909 
 
 
Theoretical calculations1) 
 The semiempirical molecular-orbital method (PM6) was used to perform the 
conformational analysis with Gaussian 09 program package. The gas phase geometry optimization 
of the molecules leading to energy minima was achieved using the B3LYP hybrid functional with 
the 6-31G(d) basis set as implemented in the Gaussian 09. For the optimized structures of the 
states, vibrational normal mode analysis was carried out to ensure that the obtained structures were 
corresponding to minimum energy state. The Mulliken charge distribution was calculated on 
B3LYP level with 6-31G (d) basis sets. 
 
1) Gaussian 09, Revision D.01, 
M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. 
Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, 
R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. 
N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. 
S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. 
Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. 
Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, 
P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, 
J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2013. 
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Figure S1. Scan of total energies of intermediate 99a generated by varying two torsion angles 
(the dihedral scans showed with u-shaped arrows, as shown in the left structure).  The arrow at 
the bottom represents the global energy minimum conformer.  
 
Table S1. Cartesian coordinates (Angstroms) for (99a): 
Point Group: C1 
Total energy = -3863.932410 hartree 
Symbol X Y Z 
C 1.346895 -1.99268 -0.14018 
C 2.542824 -1.42262 -0.43711 
C 2.785261 -0.09376 0.012257 
C 1.868794 0.621205 0.736319 
C 0.565705 0.035603 1.088738 
H 1.047491 -2.99105 -0.42482 
H 3.29116 -1.96654 -0.99719 
O -0.2987 0.585679 1.746126 
O 2.036101 1.875519 1.201676 
H 2.927871 2.176657 0.946108 
N 0.408194 -1.2705 0.559344 
S -2.00604 -1.99123 -0.21631 
C -2.62766 -0.33177 -0.27424 
C -2.33525 0.464747 -1.38129 
C -3.40723 0.139543 0.785754 
C -2.83871 1.763558 -1.41977 
H -1.73945 0.068544 -2.19595 
C -3.89684 1.437584 0.72454 
H -3.62241 -0.49936 1.634939 
C -3.61699 2.270749 -0.37135 
H -2.62279 2.39192 -2.27971 
H -4.50356 1.81564 1.543079 
C -4.13049 3.689255 -0.40208 
H -3.53032 4.332517 0.25431 
H -4.08621 4.111891 -1.4103 
H -5.16679 3.747048 -0.05169 
Br 4.465589 0.729387 -0.39927 
O -1.38222 -2.32206 -1.49394 
O -2.94548 -2.87299 0.456449 
O -0.73337 -1.94754 0.961139 
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Chapter 4: The New Hybrid Type Squaramide Fused Amino Alcohol Organocatalysts For 
Enantioselective Domino Michael Addition Cyclization Reaction  
General procedure for the synthesis of compounds (163a-k): To a 4-mL sample vial containing 
dimedone 162a (0.1 mmol) and catalyst 29a (5 mol%) added anhydrous THF (1.0 mL). The 
reaction mixture allowed to stir at 0° C for 1 h, followed by added 3-dicyano-2-indanones 161a-j 
(0.1 mmol) at same temperature. The reaction mixture was allowed stirred at the same temperature 
for 48 h. After completion of reaction, indicated by TLC, the residue was purified by using flash 
column chromatography (ethyl acetate/hexane, 4:6) to afford the desired products 163a-k in 
moderate to excellent chemical yield. The enantiomeric excess was determined by chiral HPLC 
using Chiralpak AD-H and Chiralcell OD-H columns.  
 
(3S)-2-amino-1-benzyl-7,7-dimethyl-2,5-doxo-tetrahydrospiro(chromene-4,3-indoline)-3-
carbonitrile (163b): White solid. 92 mg, 98% yield. m.p. 250-251 °C. [α]D24 = –22 (c = 0.18, 
MeOH solvent). IR (neat): cm-1 = 2962, 2189, 1706, 1632, 1492, 1470. 1H NMR (500 MHz, 
DMSO-d6, ppm): δ 7.55 (d, J = 7.00 Hz, 2H), 7.40-7.30 (m, 5H), 7.18 (t, 
J = 7.50 Hz, 1H), 7.02 (t, J = 8.00 Hz, 1H), 6.74 (d, J = 8.00 Hz, 1H), 
4.96 (q, J = 16.50, 29.50 Hz, 2H), 2.66 (q, J = 17.50, 25.00 Hz, 2H), 2.27 
(d, J = 16.50 Hz, 1H), 2.18 (d, J = 16.50 Hz, 1H), 1.10 (s, 3H), 1.07 (s, 
3H) ppm. 13C NMR (125 MHz, DMSO-d6, ppm): 195.2, 176.8, 164.6, 
159.0, 142.6, 136.2, 133.6, 128.48, 128.40, 127.2, 127.1, 123.0, 122.7, 
117.5, 110.7, 109.0, 57.2, 50.0, 46.6, 43.4, 32.0, 27.7, 27.12. MS (EI): m/z = 425 [M]+, HRMS 
(EI): calcd. for C26H23N3O3 m/z 425.1748; found: 425.1745. The enantiomeric excess was 
determined by chiral HPLC; CHIRACELL OD-H column (solvent system (80:20) Hexane/IPA; 
flow rate 0.5 mL/min; temp 25°C; detection UV 210 nm; retention time 33.38 min (major) and 
56.77 min (minor), ee = 83%).  
 
(3S)-2-amino-1-(4-methoxybenzyl)-7,7-dimethyl-2,5-doxo-tetrahydrospiro(chromene-4,3-
indoline)-3-carbonitrile (163c): White solid. 70 mg, 89% yield. m.p. 
147-149 °C. [α]D24 = –21 (c = 0.18, MeOH solvent). IR (neat): 2972, 2189, 
1707, 1470, 1370 cm-1 = 1H NMR (500 MHz, DMSO-d6, ppm): δ 7.41 (d, 
J = 8.50 Hz, 2H), 7.33 (s, 2H), 7.18-7.06 (m, 2H), 6.94 (t, J = 10.00 Hz, 
1H), 6.86 (d, J = 5.00 Hz, 2H), 6.69 (d, J = 8.00 Hz, 1H), 4.83 (q, J = 
O
N
O O
H2N
NC
Bn
163b
O
N
O O
H2N
NC
PMB
163c
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20.00, 23.50 Hz, 2H), 3.71 (s, 3H), 2.60 (q, J = 17.50, J = 29.00 Hz, 2H), 2.15 (dd, J = 16.00, 
28.00 Hz, 2H), 1.04 (s, 3H), 1.00 (s, 3H). 13C NMR (125 MHz, DMSO-d6, ppm): 195.0, 176.6, 
164.5, 158.9, 158.4, 142.6, 133.6, 128.9, 128.5, 128.2, 122.9, 122.5, 117.4, 113.7, 110.6, 109.0, 
57.2, 55.0, 49.9, 46.5, 42.7, 32.0, 27.6, 27.0. MS (EI): m/z = 455 [M]+, HRMS (EI): calcd. for 
C27H25N3O3 m/z 455.1834; found: 455.1838. The enantiomeric excess was determined by chiral 
HPLC; CHIRALCELL OD-H column (solvent system (80:20) Hexane: IPA; flow rate 0.5 
mL/min; temp 25°C; detection UV 254 nm; retention time 48.74 min (major) and 92.45 min 
(minor), ee = 81%). 
  
(3S)-2-amino-1-(tertiarybutyloxy)-7,7-dimethyl-2,5-doxo-tetrahydrospiro(chromene-4,3-
indoline)-3-carbonitrile (163d): White solid. 57 mg, 72% yield. m.p.135-136 °C. [α]D24 = –10 (c 
= 0.18, MeOH solvent). IR (neat): cm-1 = 3309, 3179, 2189, 1720, 1715, 1610, 1407, 1309.  1H 
NMR (500 MHz, DMSO-d6, ppm): δ 7.87 (d, J = 8.00 Hz, 1H), 7.30 (t, J 
= 10.00 Hz, 1H), 7.12 (t, J = 7.50 Hz, 1H), 7.02 (d, J = 6.50 Hz, 1H), 4.99 
(s, 2H), 2.56-2.46 (m, 2H), 2.23-2.13 (m, 2H), 1.65 (s, 12H), 1.11 (s, 3H), 
1.06 (s, 3H). 13C NMR (125 MHz, DMSO-d6, ppm): 195.0, 175.5, 163.9, 
158.3, 149.1, 139.8, 131.4, 129.4, 125.0, 123.2, 116.3, 115.5, 112.2, 84.6, 
50.4, 40.9, 32.4, 28.6, 28.3, 27.9. MS (FAB): m/z = 436 [M]+, HRMS (FAB): calcd. for 
C24H26N3O5 m/z 436.1845; found: 436.1863. The enantiomeric excess was determined by chiral 
HPLC; CHIRALCELL OD-H column (solvent system (Hexane/IPA) 90:10; flow rate 0.5 mL/min; 
temp 25°C; detection UV 254 nm; retention time 47.78 min (major) and 53.24 min (minor), ee = 
5%).  
 
(3S)-2-amino-1-methyl-7,7-dimethyl-2,5-doxo-tetrahydrospiro(chromene-4,3-indoline)-3-
carbonitrile (163e): White solid. 86 mg, 92% yield. m.p.195-196 °C. [α]D24 = –23 (c = 0.18, 
MeOH solvent). IR (neat): cm-1 = 3308, 3176, 2189, 1720, 1715, 1612, 1432, 1402. 1H NMR (500 
MHz, DMSO-d6, ppm): δ 7.29 (s, 1H), 7.25 (t, J = 8.00 Hz, 1H), 7.04 (d, 
J = 7.50 Hz, 1H), 7.00-6.96 (m, 2H), 3.12 (s, 3H), 2.56 (d, J = 4.00Hz, 
2H), 2.11 (q, J = 16.00, 32.50 Hz, 2H), 1.02 (s, 3H), 0.98 (s, 3H). 13C 
NMR (125 MHz, DMSO-d6, ppm): 194.9, 176.6, 164.3, 158.9, 143.5, 
137.4, 133.5, 128.9, 128.2, 125.3, 122.8, 122.4, 117.2, 110.7, 108.2, 
57.0, 49.9, 32.0, 27.5, 27.0, 26.4, 21.1. MS (EI): m/z = 349 [M]+, HRMS (FAB): calcd. for 
O
N
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C20H19N3O3 m/z 349.3814; found: 349.3820. The enantiomeric excess was determined by chiral 
HPLC; CHIRALCELL OD-H column (solvent system (Hexane: IPA) 80:20; flow rate 0.5 
mL/min; temp 25°C; detection UV 254 nm; retention time 95.54 min (major) and 48.69 min 
(minor), ee = 95%).  
 
(3S)-2-amino-1-(methylenenaphthyl)-7,7-dimethyl-2,5-doxo-tetrahydrospiro(chromene-4,3-
indoline)-3-carbonitrile (163j): White solid. 60 mg, 81% yield. m.p. 188-190 °C. [α]D24 = –11 (c 
= 0.18, solvent). IR (neat): cm-1 =   3395, 3196, 2996, 2189, 1782, 1676, 1610. 1H NMR (500 
MHz, DMSO-d6, ppm): δ 8.03 (s, 1H), 7.90-7.87 (m, 2H), 7.79-7.77 (m, 
1H), 7.61 (d, J = 8.50 Hz, 1H), 7.51-7.42 (m, 2H), 7.38 (s, 2H), 7.36 (s, 
1H), 7.10 (t, J = 7.50 Hz, 2H), 6.96 (t, J = 7.50 Hz, 1H), 6.74 (d, J = 8.00 
Hz, 1H), 5.08 (dd, J = 16.50, 68.00 Hz, 2H), 2.62 (q, J = 17.50, 28.00 Hz, 
2H), 2.19 (dd, J = 16.00, 41.00 Hz, 2H), 1.06 (s, 3H), 1.02 (s, 3H). 13C 
NMR (125 MHz, DMSO-d6, ppm): 195.1, 176.8, 164.6, 159.0, 142.6, 
133.7, 133.6, 132.9, 132.2, 128.3, 128.0, 127.6, 127.5, 126.2, 125.8, 125.5, 
125.2, 123.0, 122.6, 110.7, 108.9, 57.1, 50.0, 46.7, 43.4, 32.0, 27.6, 27.0. 
MS (EI): m/z = 475 [M]+, HRMS (FAB): calcd. for C30H25N3O3 m/z 
475.1823; found: 475.1894. The enantiomeric excess was determined by chiral HPLC; 
CHIRALCELL OD-H column (solvent system 80:20, Hexane: IPA; flow rate 1.0 mL/min; temp 
25°C; detection UV 254 nm; retention time 45.82 min (major) and 66.26 min (minor), ee = 71%).  
 
(3S)-2-amino-1-methyl-2,5-doxo-tetrahydrospiro(chromene-4,3-indoline)-3-carbonitrile 
(163k): White solid. 68 mg, 90% yield. m.p. 267-268 °C. [α]D24 = –20 (c = 0.18, MeOH solvent). 
IR (neat): cm-1 = 3302, 2187, 1723, 1671, 1629, 1293. 1H NMR (500 MHz, DMSO-d6, ppm): δ 
7.30-7.22 (m, 3H), 7.08-7.05 (m, 1H), 7.00-6.95 (m, 2H), 3.12 (s, 3H), 
2.70-2.61 (m, 2H), 2.25-2.14 (m, 2H), 1.936-1.88 (m, 2H). 13C NMR (125 
MHz, DMSO-d6, ppm): 195.0, 178.8, 159.0, 144.5, 133.5, 128.4, 122.8, 
122.5, 117.1, 110.5, 108.1, 57.0, 50.0, 46.5, 32.0, 27.6, 27.0, 26.5. MS (EI): 
m/z = 321 [M]+, HRMS (EI): calcd. for C18H15N3O3 m/z 321.3312; found: 
321.1145. The enantiomeric excess was determined by chiral HPLC; 
CHIRALPAK AD-H column (solvent system 80:20, Hexane: IPA; flow rate 1.0 mL/min; temp 
25°C; detection UV 254 nm; retention time 12.81 min (major) and 28.44 min (minor), ee = 76%).  
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